Amedeo Smart

Free Medical Literature Service

 

Amedeo

COVID-19
  Free Subscription

Articles published in
J Med Virol
    December 2023
  1. HUANG PY, Lai CC, Hsu CK
    Assessing risk factors for COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease.
    J Med Virol. 2023;95:e29281.
    >> Share

    November 2023
  2. LI S, Li X, Liang H, Yu K, et al
    SARS-CoV-2 ORF7a blocked autophagy flux by intervening in the fusion between autophagosome and lysosome to promote viral infection and pathogenesis.
    J Med Virol. 2023;95:e29200.
    >> Share

  3. MAHLA RS
    Interstitial lung diseases and COVID-19 pneumonia.
    J Med Virol. 2023;95:e29207.
    >> Share

  4. KIM IS, Kang CK, Lee SJ, Lee CH, et al
    Tracking antigen-specific TCR clonotypes in SARS-CoV-2 infection reveals distinct severity trajectories.
    J Med Virol. 2023;95:e29199.
    >> Share

  5. ZHANG YN, Zhu GH, Liu W, Chen XX, et al
    Discovery of the covalent SARS-CoV-2 M(pro) inhibitors from antiviral herbs via integrating target-based high-throughput screening and chemoproteomic approaches.
    J Med Virol. 2023;95:e29208.
    >> Share

  6. NGIAM JN, Ng OT, Toh MPHS, Gao Q, et al
    Predictors of disease severity in SARS-CoV-2 omicron variant XBB sublineages and variants of interest.
    J Med Virol. 2023;95:e29204.
    >> Share

  7. COLSON P, Bader W, Fantini J, Dudouet P, et al
    From viral democratic genomes to viral wild bunch of quasispecies.
    J Med Virol. 2023;95:e29209.
    >> Share

  8. WANG Y, Wu L, Yu X, Wang G, et al
    Development of a rapid, sensitive detection method for SARS-CoV-2 and influenza virus based on recombinase polymerase amplification combined with CRISPR-Cas12a assay.
    J Med Virol. 2023;95:e29215.
    >> Share

  9. BERGNA A, Lai A, Ventura CD, Bruzzone B, et al
    Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020 and winter 2021.
    J Med Virol. 2023;95:e29193.
    >> Share

  10. WANG B, Yang W, Tong Y, Sun M, et al
    Integrative proteomics and metabolomics study reveal enhanced immune responses by COVID-19 vaccine booster shot against Omicron SARS-CoV-2 infection.
    J Med Virol. 2023;95:e29219.
    >> Share

  11. SPRINGER DN, Reuberger E, Borsodi C, Puchhammer-Stockl E, et al
    Comparison of anti-nucleocapsid antibody assays for the detection of SARS-CoV-2 Omicron vaccine breakthroughs after various intervals since the infection.
    J Med Virol. 2023;95:e29229.
    >> Share

  12. KIM Y, Kim Y, Lim HJ, Kim DK, et al
    Integrative single-cell transcriptome analysis provides new insights into post-COVID-19 pulmonary fibrosis and potential therapeutic targets.
    J Med Virol. 2023;95:e29201.
    >> Share

  13. LIU D, Wang Z, Mao M, Zhang Z, et al
    Application of whole-genome tiling array at Shanghai port, China: An alternative method for SARS-CoV-2 surveillance.
    J Med Virol. 2023;95:e29222.
    >> Share

  14. BUCK AM, Deitchman AN, Takahashi S, Lu S, et al
    The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms.
    J Med Virol. 2023;95:e29216.
    >> Share

  15. LOW K, Moller R, Stegmann C, Becker M, et al
    Luminescent reporter cells enable the identification of broad-spectrum antivirals against emerging viruses.
    J Med Virol. 2023;95:e29211.
    >> Share

  16. ABDOLAHI T, Maamouri G, Behmadi M, Mirzaeian S, et al
    Investigating the impact of Sinopharm COVID-19 vaccination on antibody response in pregnant women and their newborns.
    J Med Virol. 2023;95:e29231.
    >> Share

  17. RIVAS G, Labiod N, Luczkowiak J, Lasala F, et al
    Superior neutralizing response after first versus second SARS-CoV-2 infection in fully vaccinated individuals.
    J Med Virol. 2023;95:e29225.
    >> Share

  18. WU JY, Liu MY, Hung KC, Hsu WH, et al
    Nutritional deficiency anemia and post-acute sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: A six-month retrospective cohort analysis of 30 892 patients.
    J Med Virol. 2023;95:e29246.
    >> Share

  19. KANG SW, Kim JW, Kim JY, Lim SY, et al
    Virological characteristics and the rapid antigen test as deisolation criteria in immunocompromised patients with COVID-19: A prospective cohort study.
    J Med Virol. 2023;95:e29228.
    >> Share

  20. LI Z, Xiong Y, Long J, Li T, et al
    Resurgence of influenza during COVID-19 in Chongqing, China: A retrospective analysis.
    J Med Virol. 2023;95:e29249.
    >> Share

  21. CHENANE HR, Lingas G, Menidjel R, Laouenan C, et al
    High sera levels of SARS-CoV-2 N antigen are associated with death in hospitalized COVID-19 patients.
    J Med Virol. 2023;95:e29247.
    >> Share

  22. WANG Z, Zhao C, Li C, Liu S, et al
    Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS-CoV-2 targeted therapy.
    J Med Virol. 2023;95:e29221.
    >> Share

  23. HU GM, Tai YC, Chen CM
    Unraveling the evolutionary patterns and phylogenomics of coronaviruses: A consensus network approach.
    J Med Virol. 2023;95:e29233.
    >> Share

  24. MAO R, Fan Z, He M, Li J, et al
    Acne and COVID-19 susceptibility, hospitalization, and severity: A genetic correlation study.
    J Med Virol. 2023;95:e29265.
    >> Share

  25. KONDO Y, Kawamura Y, Hattori F, Nakai H, et al
    Serological analysis of severe acute respiratory syndrome coronavirus 2 infection in children with Kawasaki disease.
    J Med Virol. 2023;95:e29274.
    >> Share

    October 2023
  26. SHIH HL, Lee YT, Sun CK, Chang R, et al
    Considerations regarding the long-term risk of herpes zoster following COVID-19.
    J Med Virol. 2023;95:e29130.
    >> Share

  27. FAPPANI C, Gori M, Bianchi S, Terraneo M, et al
    Differential diagnosis of fever and rash cases negative for measles and rubella to complement surveillance activities.
    J Med Virol. 2023;95:e29141.
    >> Share

  28. XU W, Wen X, Cong X, Jiang W, et al
    COVID-19 mRNA vaccine, but not a viral vector-based vaccine, promotes neutralizing anti-type I interferon autoantibody production in a small group of healthy individuals.
    J Med Virol. 2023;95:e29137.
    >> Share

  29. HOLLSTEIN MM, Dierks S, Schon MP, Bergmann A, et al
    Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
    J Med Virol. 2023;95:e29122.
    >> Share

  30. WIEDEL NA, Sayles H, Larson J, Wardian JL, et al
    Associations between COVID-19 therapies and inpatient gastrointestinal bleeding: A multisite retrospective study.
    J Med Virol. 2023;95:e29100.
    >> Share

  31. HU M, Wang X, Li B, Wang B, et al
    Fitness evaluation of SARS-CoV-2 variants: A retrospective study.
    J Med Virol. 2023;95:e29123.
    >> Share

  32. RECTOR A, Bloemen M, Van Ranst M, Wollants E, et al
    Used paper tissues for pathogen identification in acute respiratory infection.
    J Med Virol. 2023;95:e29127.
    >> Share

  33. LI X, Zhang Y, Wang J, Han J, et al
    Long-term dynamic shifts in genomic base content and evolutionary trajectories of SARS-CoV-2 variants.
    J Med Virol. 2023;95:e29128.
    >> Share

  34. LIANG T, Guo K, Ni P, Duan G, et al
    The association of sickle cell disorder with adverse outcomes in COVID-19 patients: A meta-analysis.
    J Med Virol. 2023;95:e29120.
    >> Share

  35. SHI T, Xu L, Li X, Huang L, et al
    The CD19(+) B cell as a marker for the febrile children infected with influenza A and Omicron variant.
    J Med Virol. 2023;95:e29097.
    >> Share

  36. FENG S, Fan Z, Zhou K, Ma S, et al
    Subunit vaccine raised against the SARS-CoV-2 spike of Delta and Omicron variants.
    J Med Virol. 2023;95:e29160.
    >> Share

  37. LIU J, Zhang H, Kong J, Liu S, et al
    Alleviated symptoms of SARS-CoV-2 Omicron variant infection in chronic hepatitis B patients with immune control.
    J Med Virol. 2023;95:e29173.
    >> Share

  38. BREZNIK JA, Rahim A, Bhakta H, Clare R, et al
    Early humoral and cellular responses after bivalent SARS-CoV-2 mRNA-1273.214 vaccination in long-term care and retirement home residents in Ontario, Canada: An observational cohort study.
    J Med Virol. 2023;95:e29170.
    >> Share

  39. GAO Y, Zhang Y, Mou K, Liu Y, et al
    Assessment of alterations in the retina and vitreous in pre- and post-COVID-19 patients using swept-source optical coherence tomography and angiography: A comparative study.
    J Med Virol. 2023;95:e29168.
    >> Share

  40. YI J, Li X, Zhang R, Kong L, et al
    The impact of the COVID-19 pandemic on the prevalence and genotype distribution of HPV infection in Beijing, China.
    J Med Virol. 2023;95:e29155.
    >> Share

  41. BA Z, Yang A, Zhu S, Li Y, et al
    Comprehensive evaluation of the effect of inactivated SARS-CoV-2 vaccination on female fertility: A retrospective cohort study.
    J Med Virol. 2023;95:e29161.
    >> Share

  42. HU Z, Jin Z, Zhou M, Zhang C, et al
    CoronaVac and BBIBP-CorV vaccines against SARS-CoV-2 during predominant circulation of Omicron BA.5.2 and BF.7 in China, a retrospective cohort study.
    J Med Virol. 2023;95:e29143.
    >> Share

  43. ABBASI HQ
    Comments on: Bacterial and fungal superinfections are detected at higher frequency in critically ill patients affected by SARS CoV-2 infection than negative patients and are associated to a worse outcome.
    J Med Virol. 2023;95:e29167.
    >> Share

  44. MATIC S, Milovanovic D, Mijailovic Z, Djurdjevic P, et al
    Its all about IFN-lambda4: Protective role of IFNL4 polymorphism against COVID-19-related pneumonia in females.
    J Med Virol. 2023;95:e29152.
    >> Share

  45. COLSON P, La Scola B, Beye M, Delerce J, et al
    Emergence of a second SARS-CoV-2 variant with a tremendous genetic leap from its ancestors.
    J Med Virol. 2023;95:e29124.
    >> Share

  46. WEI D, Yu X, Li Y, Chen Y, et al
    Sequential reinfection with Omicron variants elicits broader neutralizing antibody profiles in booster vaccinees and reduces the duration of viral shedding.
    J Med Virol. 2023;95:e29151.
    >> Share

  47. CHEN D, Li X, Hao X, Qiu Y, et al
    Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS-CoV-1 survivors after two doses of CoronaVac plus one dose subunit vaccine.
    J Med Virol. 2023;95:e29136.
    >> Share

  48. JIAO F, Andrianov AM, Wang L, Furs KV, et al
    Repurposing Navitoclax to block SARS-CoV-2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein.
    J Med Virol. 2023;95:e29145.
    >> Share

  49. YANG X, Hu C, Yang X, Yang X, et al
    Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice.
    J Med Virol. 2023;95:e29140.
    >> Share

  50. LIU S, Wang P, Shi X, Weng T, et al
    Maternal antibody transfer rate of vaccination against SARS-CoV-2 before or during early pregnancy and its protective effectiveness on offspring.
    J Med Virol. 2023;95:e29125.
    >> Share

  51. COLSON P, Delerce J, Fantini J, Pontarotti P, et al
    The return of the "Mistigri" (virus adaptative gain by gene loss) through the SARS-CoV-2 XBB.1.5 chimera that predominated in 2023.
    J Med Virol. 2023;95:e29146.
    >> Share

  52. DE FRANCESCO MA, Piva S, Pellizzeri S, Signorini L, et al
    Response to the Letter to the Editor on "Bacterial and fungal superinfections are detected at higher frequency in critically ill patients affected by SARS-CoV-2 infection than negative patients and are associated to a worse outcome".
    J Med Virol. 2023;95:e29192.
    >> Share

  53. WANG Q, Jia M, Jiang M, Cao Y, et al
    Increased population susceptibility to seasonal influenza during the COVID-19 pandemic in China and the United States.
    J Med Virol. 2023;95:e29186.
    >> Share

  54. MOHAMMADI-PILEHDARBONI H, Shenagari M
    Regarding the article Causal effect of COVID-19 on Alzheimer's disease: A Mendelian randomization study by Baranova et al.
    J Med Virol. 2023;95:e29176.
    >> Share

  55. CACCURI F, Messali S, Scarpa F, Giovanetti M, et al
    First detection of SARS-CoV-2 BA.2.86.1 in Italy.
    J Med Virol. 2023;95:e29175.
    >> Share

  56. LI T, Chen N, Wang X, Chen N, et al
    Epidemiology of influenza A outbreak among children after COVID-19: A single-center retrospective observational study.
    J Med Virol. 2023;95:e29174.
    >> Share

  57. AHN H, Calderon BM, Fan X, Gao Y, et al
    Structural basis of the American mink ACE2 binding by Y453F trimeric spike glycoproteins of SARS-CoV-2.
    J Med Virol. 2023;95:e29163.
    >> Share

  58. MEYERS E, Park J, Coen A, Raman L, et al
    Evaluation of a smartphone-operated point-of-care device using loop-mediated isothermal amplification technology for rapid and remote detection of SARS-CoV-2.
    J Med Virol. 2023;95:e29158.
    >> Share

  59. BASTOS V, Pacheco V, Rodrigues EDL, Moraes CNS, et al
    Neuroimmunology of rabies: New insights into an ancient disease.
    J Med Virol. 2023;95:e29042.
    >> Share

  60. HSIA NY, Hsu AY, Wang YH, Li JX, et al
    The risk assessment of uveitis after COVID-19 diagnosis: A multicenter population-based study.
    J Med Virol. 2023;95:e29188.
    >> Share

  61. QI Z, Yuan S, Wei J, Xia S, et al
    Clinical and pathological features of omicron variant of SARS-CoV-2-associated kidney injury.
    J Med Virol. 2023;95:e29196.
    >> Share

  62. ARONS E, Henry K, Haas C, Gould M, et al
    Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection.
    J Med Virol. 2023;95:e29179.
    >> Share

    September 2023

  63. Correction to "Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study".
    J Med Virol. 2023;95:e29063.
    >> Share

  64. SENGUPTA S, Shaw SK, Chatterjee S, Bhattacharya G, et al
    Perturbations in spike-specific peripheral T follicular helper cells in SARS-CoV2 breakthrough convalescent individuals immunized by BBV152 vaccine.
    J Med Virol. 2023;95:e29053.
    >> Share

  65. ZHOU H, Xie P, Qiu M, Dong S, et al
    Arbidol increases the survival rate by mitigating inflammation in suckling mice infected with human coronavirus OC43 virus.
    J Med Virol. 2023;95:e29052.
    >> Share

  66. DAS S, Kumar S
    Exploring the mechanisms of long COVID: Insights from computational analysis of SARS-CoV-2 gene expression and symptom associations.
    J Med Virol. 2023;95:e29077.
    >> Share

  67. AHLUWALIA P, Vashisht A, Singh H, Sahajpal NS, et al
    Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.
    J Med Virol. 2023;95:e29067.
    >> Share

  68. MA J, Qiu S
    Infection with critically ill COVID-19 increases the risk of cardioembolic stroke.
    J Med Virol. 2023;95:e29066.
    >> Share

  69. MOLINA IS, Jimenez-Vasquez V, Lizarraga W, Sevilla N, et al
    Sub-lineage B.1.6 of hMPXV in a global context: Phylogeny and epidemiology.
    J Med Virol. 2023;95:e29056.
    >> Share

  70. CASO JM, Fernandez-Ruiz M, Lopez-Medrano F, Caro-Teller JM, et al
    Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early-stage symptomatic COVID-19: A real-life experience.
    J Med Virol. 2023;95:e29082.
    >> Share

  71. HAO S, Ning K, Kuz CA, Xiong M, et al
    SARS-CoV-2 infection of polarized human airway epithelium induces necroptosis that causes airway epithelial barrier dysfunction.
    J Med Virol. 2023;95:e29076.
    >> Share

  72. SCARPA F, Ciccozzi M
    On the SARS-CoV-2 BA.2.86 lineage: a mutation point of view.
    J Med Virol. 2023;95:e29079.
    >> Share

  73. SCARPA F, Pascarella S, Ciccozzi A, Giovanetti M, et al
    Genetic and structural analyses reveal the low potential of the SARS-CoV-2 EG.5 variant.
    J Med Virol. 2023;95:e29075.
    >> Share

  74. SHAO C, Shi Y, Chen R, Liu X, et al
    Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic.
    J Med Virol. 2023;95:e29098.
    >> Share

  75. HOSSAIN MS, Kerkvliet JG, Hoppe AD
    Whole genome CRISPR screening strategy to identify genes contributing to SARS-CoV-2 spike and VSV-G mediated entry.
    J Med Virol. 2023;95:e29087.
    >> Share

  76. ZHANG B, Tsai YW, Wu JY, Liu TH, et al
    Risk of cytomegalovirus diseases among coronavirus disease survivors: A retrospective cohort study.
    J Med Virol. 2023;95:e29096.
    >> Share

  77. TSO WW, Kwan MY, Ip P, Chan JF, et al
    Response to the Letter to the Editor on "Clinical characteristics of unvaccinated or incompletely vaccinated children with neurological manifestations due to SARS-CoV-2 Omicron infection".
    J Med Virol. 2023;95:e29095.
    >> Share

  78. HUANG SW, Yeh WB, Chen HY, Yong SB, et al
    Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients.
    J Med Virol. 2023;95:e29101.
    >> Share

  79. HANSEN KS, Jorgensen SE, Skouboe MK, Agergaard J, et al
    Examination of autoantibodies to type I interferon in patients suffering from long COVID.
    J Med Virol. 2023;95:e29089.
    >> Share

  80. ZUO T, Liang G, Huang Z, Cao Z, et al
    Baseline gut microbiome features prior to SARS-CoV-2 infection are associated with host symptoms in and post COVID-19.
    J Med Virol. 2023;95:e29083.
    >> Share

  81. CAKIR C, Kuspinar G, Kurt G, Berber M, et al
    Comparison of semen parameters in the same patients before and after diagnosis of COVID-19.
    J Med Virol. 2023;95:e29094.
    >> Share

  82. CHU WM, Hsieh TH, Wei JC
    Comment on Tsai et al.'s "clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data".
    J Med Virol. 2023;95:e29086.
    >> Share

  83. JIANG T, Liu R, Shen J
    CRISPR dual enzyme cleavage triggers DNA and RNA substrate cleavage for SARS-CoV-2 dual gene detection.
    J Med Virol. 2023;95:e29090.
    >> Share

  84. RAFATI A, Jameie M, Amanollahi M, Jameie M, et al
    Association of seizure with COVID-19 vaccines in persons with epilepsy: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e29118.
    >> Share

  85. YULUG B, Ayyildiz B, Ayyildiz S, Sayman D, et al
    Infection with COVID-19 is no longer a public emergency: But what about degenerative dementia?
    J Med Virol. 2023;95:e29072.
    >> Share

  86. DE SOUSA LAF, Ferreira LSS, Lobato LFL, Ferreira HLDS, et al
    Molecular epidemiology of SARS-CoV-2 variants in circulation in the state of Maranhao, Brazil.
    J Med Virol. 2023;95:e29092.
    >> Share

  87. XIANG Y, Mou C, Shi K, Chen X, et al
    SADS-CoV nsp1 inhibits the IFN-beta production by preventing TBK1 phosphorylation and inducing CBP degradation.
    J Med Virol. 2023;95:e29104.
    >> Share

  88. TSAI YW, Wu JY, Liu TH, Chuang MH, et al
    Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data.
    J Med Virol. 2023;95:e29085.
    >> Share

  89. BRUZZESI E, Gabrieli A, Bernasconi D, Marchetti G, et al
    HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial.
    J Med Virol. 2023;95:e29114.
    >> Share

  90. ZHAN Y, Ye L, Ouyang Q, Yin J, et al
    The binding profile of SARS-CoV-2 with human leukocyte antigen polymorphisms reveals critical alleles involved in immune evasion.
    J Med Virol. 2023;95:e29113.
    >> Share

  91. LI B, Zhang J, Huang Y, Li X, et al
    A conserved N protein nano-vaccine of COVID-19 exerts potent and cross-reactive humoral and cellular immune responses in mice.
    J Med Virol. 2023;95:e29115.
    >> Share

  92. COELHO GM, Cataneo AHD, Raboni SM, Nogueira MB, et al
    Development of an anti-SARS-CoV-2 monoclonal antibody panel and its applicability as a reagent in high-throughput fluorescence reduction neutralization and immunohistochemistry assays.
    J Med Virol. 2023;95:e29111.
    >> Share

    August 2023
  93. ROY A, Saade C, Josset L, Clement B, et al
    Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients.
    J Med Virol. 2023;95:e28984.
    >> Share

  94. CHEN Y, Liu X, Tong Z
    Can inspiratory muscle training benefit patients with COVID-19? A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28956.
    >> Share

  95. ZENG G, Li J, Wang L, Zhang Z, et al
    Impact of corticosteroids use on midterm sequelae in survivors of COVID-19 admitted to hospital.
    J Med Virol. 2023;95:e28988.
    >> Share

  96. YU W, Guo Y, Hu T, Liu Y, et al
    Incidence and severity of SARS-CoV-2 reinfection, a multicenter cohort study in Shanghai, China.
    J Med Virol. 2023;95:e28997.
    >> Share

  97. LI X, Chen N, Wang X, Li T, et al
    Epidemiology of respiratory syncytial virus outbreak among children after the COVID-19 pandemic.
    J Med Virol. 2023;95:e29017.
    >> Share

  98. HIRATA Y, Katano H, Iida S, Mine S, et al
    Genomic analysis of SARS-CoV-2 in forensic autopsy cases of COVID-19.
    J Med Virol. 2023;95:e28990.
    >> Share

  99. VELAZQUEZ-SALINAS L
    Deciphering the evolutionary mechanisms of SARS-CoV-2: Absence of ORF8 protein and its potential advantage in the emergence of viral lineages.
    J Med Virol. 2023;95:e29002.
    >> Share

  100. ZUIN M, Mazzitelli M, Cattelan A
    Long-COVID: Is it time to revise the definition?
    J Med Virol. 2023;95:e29011.
    >> Share

  101. LIU TH, Chuang MH, Wu JY, Huang PY, et al
    Effectiveness of oral antiviral agents on long-term cardiovascular risk in nonhospitalized patients with COVID-19: A multicenter matched cohort study.
    J Med Virol. 2023;95:e28992.
    >> Share

  102. SHANG S, Fu B, Geng Y, Zhang J, et al
    Azvudine therapy of common COVID-19 in hemodialysis patients.
    J Med Virol. 2023;95:e29007.
    >> Share

  103. WANG Y, Zhao D, Xiao W, Shi J, et al
    Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge.
    J Med Virol. 2023;95:e29014.
    >> Share

  104. ZHIYANOV A, Shkurnikov M, Nersisyan A, Hui C, et al
    The signature of SARS-CoV-2 evolution reflects selective pressures within human guts.
    J Med Virol. 2023;95:e28996.
    >> Share

  105. ABBASI HQ
    Comments on: Clinical characteristics of unvaccinated or incompletely vaccinated children with neurological manifestations due to SARS-CoV-2 Omicron infection.
    J Med Virol. 2023;95:e29008.
    >> Share

  106. MOHAMMADI B, Dua K, Saghafi M, Singh SK, et al
    COVID-19-induced autoimmune thyroiditis: Exploring molecular mechanisms.
    J Med Virol. 2023;95:e29001.
    >> Share

  107. WASSERMAN EB, Sills AK, Martins D, Casolaro A, et al
    Factors associated with antibody titer levels among an occupational cohort of fully vaccinated individuals and subsequent risk of COVID-19 infection: A cohort study.
    J Med Virol. 2023;95:e28999.
    >> Share

  108. THURLAPATI A, McGann M, Davis JA, Granger K, et al
    Role of tixagevimab-cilgavimab in preventing SARS-CoV-2 in hematopoietic stem cell transplant and chimeric antigen receptor T-cell therapy recipients.
    J Med Virol. 2023;95:e29027.
    >> Share

  109. BAI Y, Shen L, Sun M, Yang Z, et al
    The short and long-term impact of nonpharmaceutical interventions on the prevalence of varicella in Xi'an during the COVID-19 pandemic.
    J Med Virol. 2023;95:e29020.
    >> Share

  110. LIU M, Zhang J, Li L, Tian J, et al
    Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescents.
    J Med Virol. 2023;95:e28998.
    >> Share

  111. GIOVANETTI M, Branda F, Cella E, Scarpa F, et al
    Epidemic history and evolution of an emerging threat of international concern, the severe acute respiratory syndrome coronavirus 2.
    J Med Virol. 2023;95:e29012.
    >> Share

  112. HOQUE SA, Pham NTK, Onda-Shimizu Y, Nishimura S, et al
    Sapovirus infections in Japan before and after the emergence of the COVID-19 pandemic: An alarming update.
    J Med Virol. 2023;95:e29023.
    >> Share

  113. ISHISAKA Y, Aikawa T, Malik A, Kampaktsis PN, et al
    Association of Remdesivir use with bradycardia: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e29018.
    >> Share

  114. SUN Z, Wang S, Sun X, Shi Y, et al
    COVID-19 has causal effects on cancer risk? Something we might ignore.
    J Med Virol. 2023;95:e29034.
    >> Share

  115. BAUER C, Mack E, Hefter V, Fischer A, et al
    Impaired systemic nucleocapsid antigen clearance in severe COVID-19.
    J Med Virol. 2023;95:e29032.
    >> Share

  116. MAK WA, Visser W, van der Vliet M, Markus HY, et al
    Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
    J Med Virol. 2023;95:e28989.
    >> Share

  117. DAS A, Meng W, Liu Z, Hasib MM, et al
    Molecular and immune signatures, and pathological trajectories of fatal COVID-19 lungs defined by in situ spatial single-cell transcriptome analysis.
    J Med Virol. 2023;95:e29009.
    >> Share

  118. LU S, Luo S, Bai B, Fan Z, et al
    Omicron breakthrough infections in wild-type SARS-CoV-2 vaccinees elicit high levels of neutralizing antibodies against pangolin coronavirus GX_P2V.
    J Med Virol. 2023;95:e29031.
    >> Share

  119. FANG C, Yan W, Chen Y, Dou Z, et al
    Long-term SARS-CoV-2 neutralizing antibody level prediction using multimodal deep learning: A prospective cohort study on longitudinal data in Wuhan, China.
    J Med Virol. 2023;95:e29036.
    >> Share

  120. FOURIE E, Bording ES, Euser SM, Badoux P, et al
    Nasal discharge: A unique enhanced alternative for the detection of respiratory pathogens in adults.
    J Med Virol. 2023;95:e29047.
    >> Share

  121. ZHAO Y, Zhao Y, Zhu J, Lei L, et al
    Association of inactivated COVID-19 vaccination with maternal coagulation function in early pregnancy.
    J Med Virol. 2023;95:e29051.
    >> Share

  122. GUO H, Yin M, Liu Y, Wang B, et al
    COVID-19 infection after oocyte retrieval did not have detrimental effects on embryo implantation for frozen embryo transfer.
    J Med Virol. 2023;95:e29054.
    >> Share

  123. BASTO-ABREU A, Carnalla M, Torres-Ibarra L, Sanchez-Pajaro A, et al
    SARS-CoV-2 seroprevalence and vaccine coverage from August to November 2021: A nationally representative survey in Mexico.
    J Med Virol. 2023;95:e29038.
    >> Share

  124. ZHAO Y, Zhang H, Zhao Z, Liu F, et al
    Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial.
    J Med Virol. 2023;95:e29035.
    >> Share

  125. GONDIM RNDG, de Arruda EAG, Neto RDJP, Medeiros MS, et al
    Cytokines, chemokines, and cells growth factors in patients with mild to moderate SARS-CoV-2 infection: A case-control study.
    J Med Virol. 2023;95:e29044.
    >> Share

  126. NGUYEN NN, Houhamdi L, Meddeb L, Colson P, et al
    Reinfection with SARS-CoV-2 Omicron BA.4 and BA.5 variants.
    J Med Virol. 2023;95:e29033.
    >> Share

  127. SILVA MFS, de Oliveira FCE, Pinto ACMD, Luciano MCDS, et al
    Antibody response following the fourth SARS-CoV-2 vaccine dose during the Omicron wave in Brazil.
    J Med Virol. 2023;95:e29055.
    >> Share

  128. GUTERRES A
    Viral load: We need a new look at an old problem?
    J Med Virol. 2023;95:e29061.
    >> Share

  129. YANG H, Wang Z, Zhang Y, Xu M, et al
    Clinical characteristics and factors for serious outcomes among outpatients infected with the Omicron subvariant BF.7.
    J Med Virol. 2023;95:e28977.
    >> Share

  130. LIAO HC, Huang MS, Chiu FF, Chai KM, et al
    Co-delivery of a trimeric spike DNA and protein vaccine with aluminum hydroxide enhanced Th1-dominant humoral and cellular immunity against SARS-CoV-2.
    J Med Virol. 2023;95:e29040.
    >> Share

    July 2023
  131. SOLIS M, Benotmane I, Gallais F, Caillard S, et al
    Torque teno virus viral load predicts SARS-CoV-2 vaccine response in kidney transplant recipients.
    J Med Virol. 2023;95:e28936.
    >> Share

  132. ZHAO Q, Wang X, Zhang Z, Liu X, et al
    Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
    J Med Virol. 2023;95:e28932.
    >> Share

  133. KHAN M, Khan K, Motwani J
    Comment on "Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients".
    J Med Virol. 2023;95:e28938.
    >> Share

  134. TSO WW, Kwan MY, Kwok JS, Tsang JO, et al
    Clinical characteristics of unvaccinated or incompletely vaccinated children with neurological manifestations due to SARS-CoV-2 Omicron infection.
    J Med Virol. 2023;95:e28895.
    >> Share

  135. GATES S, Andreani J, Dewar R, Smith DB, et al
    Postpandemic rebound of adeno-associated virus type 2 (AAV2) infections temporally associated with an outbreak of unexplained severe acute hepatitis in children in the United Kingdom.
    J Med Virol. 2023;95:e28921.
    >> Share

  136. ALBERT E, Fernandez-Soto D, Gimenez E, Casanovas JM, et al
    Antibody-dependent NK-cell and neutralizing antibody responses against the Spike protein of Wuhan-Hu-1 and Omicron BA.1 SARS-CoV-2 variants in vaccinated experienced and vaccinated naive individuals.
    J Med Virol. 2023;95:e28900.
    >> Share

  137. HUANG PY, Liu TH, Wu JY, Tsai YW, et al
    Response to the letter to the editor on "Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials".
    J Med Virol. 2023;95:e28918.
    >> Share

  138. YI S, Zhang SS, Wang XR, Zhou Y, et al
    Dynamics of parainfluenza virus among hospitalized children with acute respiratory tract infection under two-child policy and COVID-19 pandemic in Hubei Province, China, 2014-2022.
    J Med Virol. 2023;95:e28899.
    >> Share

  139. ZHANG H, Lu Z, Yang F, Chen H, et al
    Symptom profiles and vaccination status for COVID-19 after the adjustment of the dynamic zero-COVID policy in China: An observational study.
    J Med Virol. 2023;95:e28893.
    >> Share

  140. RAMUNNO M, Savitz R
    COVID-19 vaccination and decreased death rates: A county-level study in Pennsylvania.
    J Med Virol. 2023;95:e28883.
    >> Share

  141. DE FRANCESCO MA, Signorini L, Piva S, Pellizzeri S, et al
    Bacterial and fungal superinfections are detected at higher frequency in critically ill patients affected by SARS CoV-2 infection than negative patients and are associated to a worse outcome.
    J Med Virol. 2023;95:e28892.
    >> Share

  142. RAHMATI M, Yon DK, Lee SW, Soysal P, et al
    New-onset neurodegenerative diseases as long-term sequelae of SARS-CoV-2 infection: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28909.
    >> Share

  143. MIELKE A, Denwood M, Christiansen LE
    Estimating true prevalence through questionnaire data.
    J Med Virol. 2023;95:e28908.
    >> Share

  144. CHUNG HY, Jian MJ, Chang CK, Lin JC, et al
    Accelerating pandemic response with the emergency Omicron RT-PCR test: A comprehensive solution for COVID-19 diagnosis and tracking.
    J Med Virol. 2023;95:e28914.
    >> Share

  145. GUO Z, Jin Q, Li P, Xing G, et al
    Potential cross-species transmission risks of emerging swine enteric coronavirus to human beings.
    J Med Virol. 2023;95:e28919.
    >> Share

  146. SENDI P, Widmer N, Branca M, Thierstein M, et al
    Do quantitative levels of antispike-IgG antibodies aid in predicting protection from SARS-CoV-2 infection? Results from a longitudinal study in a police cohort.
    J Med Virol. 2023;95:e28904.
    >> Share

  147. KANG SY, Yoo JR, Park Y, Kim SH, et al
    Fatal outcome of severe fever with thrombocytopenia syndrome (SFTS) and severe and critical COVID-19 is associated with the hyperproduction of IL-10 and IL-6 and the low production of TGF-beta.
    J Med Virol. 2023;95:e28894.
    >> Share

  148. LIN WC, Wei JC
    Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients.
    J Med Virol. 2023;95:e28903.
    >> Share

  149. LIU TH, Wu JY, Huang PY, Tsai YW, et al
    The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19.
    J Med Virol. 2023;95:e28951.
    >> Share

  150. AN Y, Zhao G, Duan H, Zhang N, et al
    Robust and protective immune responses induced by heterologous prime-boost vaccination with DNA-protein dimeric RBD vaccines for COVID-19.
    J Med Virol. 2023;95:e28948.
    >> Share

  151. MA Q, Xu G
    New-onset and relapsed thrombotic microangiopathy post-COVID-19 vaccination.
    J Med Virol. 2023;95:e28946.
    >> Share

  152. GHAZIZADEH ESSLAMI G, Mamishi S, Pourakbari B, Mahmoudi S, et al
    Systematic review and meta-analysis on the serological, immunological, and cardiac parameters of the multisystem inflammatory syndrome (MIS-C) associated with SARS-CoV-2 infection.
    J Med Virol. 2023;95:e28927.
    >> Share

  153. CHEN YC, Ho CH, Liu TH, Wu JY, et al
    Response to the letter to the editor on "Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients".
    J Med Virol. 2023;95:e28945.
    >> Share

  154. HUANG Y, Zhu X, Guo X, Zhou Y, et al
    Advances in mRNA vaccines for viral diseases.
    J Med Virol. 2023;95:e28924.
    >> Share

  155. HUANG C
    Comment on Huang PS et al. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials. Med Virol. 2023; 95: e28621.
    J Med Virol. 2023;95:e28907.
    >> Share

  156. CHEN H, Ye B, Su W, Song Y, et al
    The causal role of gut microbiota in susceptibility and severity of COVID-19: A bidirectional Mendelian randomization study.
    J Med Virol. 2023;95:e28880.
    >> Share

  157. KOZAWA K, Kawamura Y, Hattori F, Miura H, et al
    Changes in trends of pediatric beta- and gamma-herpesvirus infections during the COVID-19 pandemic: A single-center observational study.
    J Med Virol. 2023;95:e28925.
    >> Share

  158. KIRSCH JA, Slutske WS, McCarthy DE, Smith SS, et al
    Factors associated with 60-day readmission among inpatients with COVID-19 at 21 United States health systems.
    J Med Virol. 2023;95:e28972.
    >> Share

  159. YANG H, Wang Z, Jiang C, Zhang Y, et al
    Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: Results of a real-world study.
    J Med Virol. 2023;95:e28947.
    >> Share

  160. PONIEDZIALEK B, Rzymski P, Zarebska-Michaluk D, Rogalska M, et al
    Short-term exposure to ambient air pollution and COVID-19 severity during SARS-CoV-2 Delta and Omicron waves: A multicenter study.
    J Med Virol. 2023;95:e28962.
    >> Share

  161. KIM Y, Kim S, Kim HJ, Kwon R, et al
    National trends in body mass index, overweight, and obesity among adults before and during the COVID-19 pandemic in 2009-2021: A representative longitudinal serial study in South Korea.
    J Med Virol. 2023;95:e28958.
    >> Share

  162. FANG Q, He X, Zheng X, Fu Y, et al
    Verifying AXL and putative proteins as SARS-CoV-2 receptors by DnaE intein-based rapid cell-cell fusion assay.
    J Med Virol. 2023;95:e28953.
    >> Share


  163. Retraction: Zhang, N, Qi, X, Chang, H, et al. Combined effects of inflammation and coronavirus disease 2019 (COVID-19) on the risks of anxiety and depression: a cross-sectional study based on UK Biobank. J Med Virol. 2023; 95:e28726. doi:10.1002/jmv.2
    J Med Virol. 2023;95:e28937.
    >> Share

  164. HE J, Mei Q, Peng Y, Xie J, et al
    Are the original SARS-CoV-2 novel mutants from in vitro culture able to escape the immune response?
    J Med Virol. 2023;95:e28931.
    >> Share


  165. Correction to "Long-Term Risk of Herpes Zoster Following Covid-19: A Retrospective Cohort Study of 2 442 686 Patients".
    J Med Virol. 2023;95:e28944.
    >> Share

  166. QU Y, Wang W, Xiao MZX, Zheng Y, et al
    The interplay between lipid droplets and virus infection.
    J Med Virol. 2023;95:e28967.
    >> Share


  167. Correction to "Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: a systematic review and meta-analysis of randomized control trials".
    J Med Virol. 2023;95:e28916.
    >> Share


  168. Correction to "SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2".
    J Med Virol. 2023;95:e28935.
    >> Share

  169. AUGUSTINE G, Sisila V, Indhu M, Gupta D, et al
    Redirecting the JAK-STAT signal blocks the SARS-CoV-2 replication.
    J Med Virol. 2023;95:e28965.
    >> Share

  170. VISOS-VARELA I, Zapata-Cachafeiro M, Pintos-Rodriguez S, Bugarin-Gonzalez R, et al
    Outpatient atorvastatin use and severe COVID-19 outcomes: A population-based study.
    J Med Virol. 2023;95:e28971.
    >> Share

  171. SHARIQ M, Malik AA, Sheikh JA, Hasnain SE, et al
    Regulation of autophagy by SARS-CoV-2: The multifunctional contributions of ORF3a.
    J Med Virol. 2023;95:e28959.
    >> Share

  172. WATANABE A, Malik A, Aikawa T, Briasoulis A, et al
    Extracorporeal membrane oxygenation for COVID-19-associated acute respiratory distress syndrome: A nationwide analysis.
    J Med Virol. 2023;95:e28961.
    >> Share

    June 2023
  173. LIN YY, Yao R, Zhuang J, Wang B, et al
    PACT inhibits the replication of SARS-CoV-2 through the blockage of GSK-3beta-N-nsp3 cascade.
    J Med Virol. 2023;95:e28832.
    >> Share

  174. RAHMATI M, Yon DK, Lee SW, Udeh R, et al
    New-onset type 1 diabetes in children and adolescents as postacute sequelae of SARS-CoV-2 infection: A systematic review and meta-analysis of cohort studies.
    J Med Virol. 2023;95:e28833.
    >> Share

  175. QIAN X, Wu B, Chen X, Peng H, et al
    Multi-omic and comparative analyses revealed monocyte-derived alpha-defensin-1 correlated with COVID-19 severity and inhibited SARS-CoV-2 infection.
    J Med Virol. 2023;95:e28845.
    >> Share

  176. REN Y, Wang G, Han D
    Statins in hospitalized COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.
    J Med Virol. 2023;95:e28823.
    >> Share

  177. GUO M, Zhu J, Hu Z, Wang Q, et al
    Histone mRNA polyadenylation-mediated inflammation underlies various virus infections and cancers.
    J Med Virol. 2023;95:e28826.
    >> Share

  178. ZENG G, Wang L, Li J, Zhang Z, et al
    Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19.
    J Med Virol. 2023;95:e28836.
    >> Share

  179. BOSKOVIC B, Bilic I, Soda J, Kero I, et al
    Transcranial magnetic stimulation in assessment of vocal cord paralysis due to post-viral (COVID-19) vagal neuropathy.
    J Med Virol. 2023;95:e28838.
    >> Share

  180. MONDI A, Mastrorosa I, Piselli P, Cimaglia C, et al
    Evolution of SARS-CoV-2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: Impact on clinical outcomes.
    J Med Virol. 2023;95:e28831.
    >> Share

  181. GAULT N, Bachelet D, Laouenan C, Borie R, et al
    Impact of corticosteroids use on midterm sequelae in survivors of COVID-19 admitted to hospital: A prospective cohort study.
    J Med Virol. 2023;95:e28819.
    >> Share

  182. MESSALI S, Rondina A, Giovanetti M, Bonfanti C, et al
    Traceability of SARS-CoV-2 transmission through quasispecies analysis.
    J Med Virol. 2023;95:e28848.
    >> Share

  183. RAHMATI M, Udeh R, Yon DK, Lee SW, et al
    A systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: A call to action for neurological, physical, and psychological sciences.
    J Med Virol. 2023;95:e28852.
    >> Share

  184. RANARD BL, Chow CC, Megjhani M, Asgari S, et al
    A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound.
    J Med Virol. 2023;95:e28854.
    >> Share

  185. REDLBERGER-FRITZ M, Springer DN, Aberle SW, Camp JV, et al
    Respiratory syncytial virus surge in 2022 caused by lineages already present before the COVID-19 pandemic.
    J Med Virol. 2023;95:e28830.
    >> Share

  186. YU W, Wang J, Yang Y, Tang C, et al
    SARS-CoV-2 Omicron (B.1.1.529) infection in rhesus macaques, hamsters, and BALB/c mice with severe lung histopathological damage.
    J Med Virol. 2023;95:e28846.
    >> Share

  187. OH T, Kim G, Baek SH, Woo Y, et al
    Comparative spatial transcriptomic profiling of severe acute respiratory syndrome coronavirus 2 Delta and Omicron variants infections in the lungs of cynomolgus macaques.
    J Med Virol. 2023;95:e28847.
    >> Share

  188. LI J, Wang B, He X, Li Z, et al
    Epidemiological characteristics of norovirus infection in pediatric patients during the COVID-19 pandemic.
    J Med Virol. 2023;95:e28874.
    >> Share

  189. TSAI YW, Wu JY, Liu TH, Chuang MH, et al
    Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data.
    J Med Virol. 2023;95:e28869.
    >> Share

  190. WU JY, Liu MY, Liu TH, Chuang MH, et al
    Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19.
    J Med Virol. 2023;95:e28866.
    >> Share

  191. FENG K, Zhang HJ, Min YQ, Zhou M, et al
    SARS-CoV-2 NSP13 interacts with host IRF3, blocking antiviral immune responses.
    J Med Virol. 2023;95:e28881.
    >> Share

  192. PEREZ-CATALAN I, Gomez-Alfaro I, Garcia-Munoz S, Roig-Marti C, et al
    Antiviral treatment or mAbs for persistent SARS-COV-2 infection in patients with hematologic malignancies: A case series.
    J Med Virol. 2023;95:e28865.
    >> Share

  193. LI F, Xu K, Pan Y, Liu P, et al
    Stability of SARS-CoV-2 and persistence of viral nucleic acids on common foods and widely used packaging material surfaces.
    J Med Virol. 2023;95:e28871.
    >> Share

  194. YE RZ, Gong C, Cui XM, Liu JY, et al
    Continuous evolution and emerging lineage of seasonal human coronaviruses: A multicenter surveillance study.
    J Med Virol. 2023;95:e28861.
    >> Share

  195. DOBROWOLSKA K, Zarebska-Michaluk D, Poniedzialek B, Jaroszewicz J, et al
    Overview of autoantibodies in COVID-19 convalescents.
    J Med Virol. 2023;95:e28864.
    >> Share

  196. KO M, Lee JY, Shin YS, Jeon S, et al
    Novel SARS-CoV-2 entry inhibitors, 2-anilinoquinazolin-4(3H)-one derivatives, show potency as SARS-CoV-2 antivirals in a human ACE2 transgenic mouse model.
    J Med Virol. 2023;95:e28863.
    >> Share

  197. CROOKS CJ, West J, Gazis T, Simmonds M, et al
    Maximal temperature varies by sex and ethnic group in hospital in-patients with Covid-19 infection.
    J Med Virol. 2023;95:e28837.
    >> Share

  198. VASCONCELOS MW, de Barros FRO, Pilonetto JC, Rosa SGB, et al
    Relationship between SARS-CoV-2 vaccination and cases, program breakthrough cases, and deaths in Dois Vizinhos, Parana, Brazil.
    J Med Virol. 2023;95:e28882.
    >> Share

  199. WATANABE Y, Yamamoto H, Matsuba I, Watanabe K, et al
    Time-series transcriptome analysis of peripheral blood mononuclear cells obtained from individuals who received the SARS-CoV-2 mRNA vaccine.
    J Med Virol. 2023;95:e28884.
    >> Share

  200. AHMADI AS, Zadheidar S, Sadeghi K, Nejati A, et al
    SARS-CoV-2 intrahost evolution in immunocompromised patients in comparison with immunocompetent populations after treatment.
    J Med Virol. 2023;95:e28877.
    >> Share

  201. RAMJATTUN K, Ma X, Gao SJ, Singh H, et al
    COVID-19db linkage maps of cell surface proteins and transcription factors in immune cells.
    J Med Virol. 2023;95:e28887.
    >> Share

  202. CAO G, Guo Z, Liu J, Liu M, et al
    Change from low to out-of-season epidemics of influenza in China during the COVID-19 pandemic: A time series study.
    J Med Virol. 2023;95:e28888.
    >> Share

  203. XIE Y, Yang M, Zhou P, Fan J, et al
    New-onset pemphigus foliaceus after COVID-19 infection.
    J Med Virol. 2023;95:e28867.
    >> Share

  204. TRAGNI V, Mercurio I, Paoletti DP, Onofrio A, et al
    Deconstructing SARS-CoV-2 neutralization: A modular molecular framework for computational design and comparison of antibodies and nanobodies targeting the spike RBD.
    J Med Virol. 2023;95:e28875.
    >> Share

  205. LUO J, Zhang J, Tang HT, Wong HK, et al
    Prevalence and risk factors of long COVID 6-12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong.
    J Med Virol. 2023;95:e28862.
    >> Share

  206. YETMAR ZA, Yao JD, Razonable RR
    SARS-CoV-2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients.
    J Med Virol. 2023;95:e28885.
    >> Share

  207. ZHENG L, Wang L, Lu F
    Looking back on the outbreak of acute severe hepatitis with unknown etiology in children in 2022: What do we know now and where do we go from here?
    J Med Virol. 2023;95:e28890.
    >> Share

  208. AMANI B, Akbarzadeh A, Amani B, Shabestan R, et al
    Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28889.
    >> Share

    May 2023
  209. MUHAMMED OA, Tawfeeq HM, Al-Jaf SMA, Niranji SS, et al
    Comments on "Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers".
    J Med Virol. 2023;95:e28822.
    >> Share

  210. SONG R, Chen X, Li B, Zhang H, et al
    Nasal spray of an IgM-like ACE2 fusion protein HH-120 accelerates SARS-CoV-2 clearance: A single-center propensity score-matched cohort study.
    J Med Virol. 2023;95:e28805.
    >> Share

  211. ALI AM, Tofiq AM, Rostam HM, Ali KM, et al
    Response to comments to the editor on "Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers".
    J Med Virol. 2023;95:e28820.
    >> Share

  212. ALI AM, Tofiq AM, Rostam HM, Ali KM, et al
    Corrigendum on "Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers".
    J Med Virol. 2023;95:e28824.
    >> Share

  213. VARGHESE R, Pai S, Kumar D, Sharma R, et al
    SARS-CoV-2 XBB.1.16 variant: India in focus?
    J Med Virol. 2023;95:e28829.
    >> Share

  214. PARCZEWSKI M, Kufel J, Aksak-Was B, Piwnik J, et al
    Artificial neural network based prediction of the lung tissue involvement as an independent in-hospital mortality and mechanical ventilation risk factor in COVID-19.
    J Med Virol. 2023;95:e28787.
    >> Share

  215. ZHANG Y, Liu J, Li H, Yuan F, et al
    Comparison of the immunogenicity of nasal-spray rVSV vector, adenovirus vector, and inactivated COVID-19-based vaccines in rodent models.
    J Med Virol. 2023;95:e28806.
    >> Share

  216. SONG J, Wu Y, Yin X, Ma H, et al
    The causal links between gut microbiota and COVID-19: A Mendelian randomization study.
    J Med Virol. 2023;95:e28784.
    >> Share

  217. ZENG G, He F, Zhang X, Li G, et al
    Antibody response to the third dose of inactivated COVID-19 vaccine in people living with HIV (PLWH): A longitudinal cohort.
    J Med Virol. 2023;95:e28797.
    >> Share

  218. BEGUM F, Srivastava AK, Tripathi PP, Ray U, et al
    A substrate for a cell free in vitro assay system to screen drugs targeting trypsin like protease-based cleavage of SARS-CoV-2 spike glycoprotein and viral entry.
    J Med Virol. 2023;95:e28796.
    >> Share

  219. LIU TH, Huang PY, Wu JY, Chuang MH, et al
    Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data.
    J Med Virol. 2023;95:e28801.
    >> Share

  220. YIN Y, Lin J, Yuan S, Tong S, et al
    Vaccination status for mild and asymptomatic infections with SARS-CoV-2 Omicron BA.2 variant in Shanghai.
    J Med Virol. 2023;95:e28767.
    >> Share

  221. HUESPE IA, Ferraris A, Lalueza A, Valdez PR, et al
    COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes. A multicontinental cohort study.
    J Med Virol. 2023;95:e28786.
    >> Share

  222. SEVGI DY, Demirbas ND, Genc Yaman I, Derin O, et al
    Evaluation of the late presentation and associated factors of people living with HIV in Turkey.
    J Med Virol. 2023;95:e28781.
    >> Share

  223. CHEN L, Zhang Q, Li H, Ma K, et al
    Clinical considerations for a gastric Dieulafoy's disease patient: Cardiac arrhythmias caused by SARS-CoV-2 or terlipressin?
    J Med Virol. 2023;95:e28792.
    >> Share

  224. OGUNBAYO AE, Mogotsi MT, Sondlane H, Sabiu S, et al
    Metagenomics characterization of respiratory viral RNA pathogens in children under five years with severe acute respiratory infection in the Free State, South Africa.
    J Med Virol. 2023;95:e28753.
    >> Share

  225. FONG SW, Goh YS, Torres-Ruesta A, Chang ZW, et al
    Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection.
    J Med Virol. 2023;95:e28774.
    >> Share

  226. WANLAPAKORN N, Kanokudom S, Phowatthanasathian H, Chansaenroj J, et al
    Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.
    J Med Virol. 2023;95:e28758.
    >> Share

  227. RIAD A, Schulz-Weidner N, Dziedzic A, Howaldt HP, et al
    Oral side effects of COVID-19 vaccines in 32 European countries: Analysis of EudraVigilance reports.
    J Med Virol. 2023;95:e28771.
    >> Share

  228. TIRELLI U, Franzini M, Chirumbolo S
    Post-COVID syndrome, the real matter of debate.
    J Med Virol. 2023;95:e28785.
    >> Share

  229. QIU S, Zheng K, Hu Y, Liu G, et al
    Genetic correlation, causal relationship, and shared loci between vitamin D and COVID-19: A genome-wide cross-trait analysis.
    J Med Virol. 2023;95:e28780.
    >> Share

  230. FORTHAL DN
    Comment on the immunogenicity of the Noora vaccine against SARS-CoV-2.
    J Med Virol. 2023;95:e28731.
    >> Share

  231. SAKAI-TAGAWA Y, Yamayoshi S, Halfmann PJ, Wilson N, et al
    Sensitivity of rapid antigen tests for Omicron subvariants of SARS-CoV-2.
    J Med Virol. 2023;95:e28788.
    >> Share

  232. SCHUURMANS STEKHOVEN SJ, Winkel KGT, Souverein D, Sondermeijer BM, et al
    Clinical validation of novel dried blood spot based collecting device using serum separation for measuring SARS-CoV-2 antibodies.
    J Med Virol. 2023;95:e28765.
    >> Share

  233. ZHANG Y, Clarke SP, Wu H, Li W, et al
    A comprehensive overview on the transmission, pathogenesis, diagnosis, treatment, and prevention of SARS-CoV-2.
    J Med Virol. 2023;95:e28776.
    >> Share

  234. NASCIMENTO JHFD, Andrade AB, Gusmao-Cunha A, Cunha AMG, et al
    Trends in the morbidity and mortality of coronavirus disease 2019 in different ethnic groups and gender in a large Brazilian city.
    J Med Virol. 2023;95:e28794.
    >> Share

    April 2023
  235. WU J, Liu W, Zhu L, Li N, et al
    Dysbiosis of oropharyngeal microbiome and antibiotic resistance in hospitalized COVID-19 patients.
    J Med Virol. 2023;95:e28727.
    >> Share

  236. BOUKHALFA Y, Stambouli N, Driss A, Daiki M, et al
    sCXCL16 as a prognostic biomarker for COVID-19 outcome.
    J Med Virol. 2023;95:e28728.
    >> Share

  237. ZHANG N, Qi X, Chang H, Li C, et al
    Combined effects of inflammation and coronavirus disease 2019 (COVID-19) on the risks of anxiety and depression: A cross-sectional study based on UK Biobank.
    J Med Virol. 2023;95:e28726.
    >> Share

  238. MENG M, Wu Y, Sha W, Zeng R, et al
    Associations of habitual glucosamine use with SARS-CoV-2 infection and hospital admission and death with COVID-19: Evidence from a large population based cohort study.
    J Med Virol. 2023;95:e28720.
    >> Share

  239. PATINO LH, Ballesteros N, Munoz M, Ramirez AL, et al
    Mu SARS-CoV-2 (B.1.621) variant: A genomic snapshot across the Colombian-Venezuelan border.
    J Med Virol. 2023;95:e28766.
    >> Share

  240. LI J, Bai H, Qiao H, Du C, et al
    Causal effects of COVID-19 on cancer risk: A Mendelian randomization study.
    J Med Virol. 2023;95:e28722.
    >> Share

  241. CENAT JM, Moshirian Farahi SMM, Bakombo SM, Dalexis RD, et al
    Vaccine mistrust among Black individuals in Canada: The major role of health literacy, conspiracy theories, and racial discrimination in the healthcare system.
    J Med Virol. 2023;95:e28738.
    >> Share

  242. CAMACHO J, Albert E, Alvarez-Rodriguez B, Rusu L, et al
    A machine learning model for predicting serum neutralizing activity against Omicron SARS-CoV-2 BA.2 and BA.4/5 sublineages in the general population.
    J Med Virol. 2023;95:e28739.
    >> Share

  243. SHANG W, Zhang S, Qian H, Pan X, et al
    Association of gut microbiota with COVID-19 susceptibility and severity: A two-sample Mendelian randomization study.
    J Med Virol. 2023;95:e28734.
    >> Share

  244. ZHAO Y, Zhao Y, Su X, Zhou Y, et al
    No association of vaccination with inactivated COVID-19 vaccines before conception with pregnancy complications and adverse birth outcomes: A cohort study of 5457 Chinese pregnant women.
    J Med Virol. 2023;95:e28735.
    >> Share

  245. VANLERBERGHE B, Vrij C, Bogaerts K, Vermeersch P, et al
    SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients.
    J Med Virol. 2023;95:e28736.
    >> Share

  246. LU T, Chen Z, Cao Y, Ao L, et al
    Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study.
    J Med Virol. 2023;95:e28730.
    >> Share

  247. CHEN YC, Ho CH, Liu TH, Wu JY, et al
    Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients.
    J Med Virol. 2023;95:e28745.
    >> Share

  248. YE J, Shao X, Yang Y, Zhu F, et al
    Predicting the negative conversion time of nonsevere COVID-19 patients using machine learning methods.
    J Med Virol. 2023;95:e28747.
    >> Share

  249. ONG DSY, de Man P, Verhagen T, Doejaaren G, et al
    Airborne virus shedding of the alpha, delta, omicron SARS-CoV-2 variants and influenza virus in hospitalized patients.
    J Med Virol. 2023;95:e28748.
    >> Share

  250. SAENZ-ALDEA M, Salgado-Barreira A, Taracido-Trunk M, Pineiro-Lamas M, et al
    RE: Colchicine and risk of hospitalization due to COVID-19: A population-based study.
    J Med Virol. 2023;95:e28741.
    >> Share

  251. CHEN L, Shao Z, Liu H, Shi Q, et al
    Clinical observation of neutralizing antibody DXP-604 for treatment critical COVID-19 patients infected with SARS-CoV-2 Delta variant.
    J Med Virol. 2023;95:e28742.
    >> Share

  252. NING J, Wang Q, Chen Y, He T, et al
    Immunodominant SARS-CoV-2-specific CD4(+) and CD8(+) T-cell responses elicited by inactivated vaccines in healthy adults.
    J Med Virol. 2023;95:e28743.
    >> Share

  253. CHEEMA HA, Rehman AU, Elrashedy AA, Mohsin A, et al
    Antiandrogens for the treatment of COVID-19 patients: A meta-analysis of randomized controlled trials.
    J Med Virol. 2023;95:e28740.
    >> Share

  254. MAO S, Cai X, Niu S, Wei J, et al
    TRIM21 promotes ubiquitination of SARS-CoV-2 nucleocapsid protein to regulate innate immunity.
    J Med Virol. 2023;95:e28719.
    >> Share

  255. DENG G, Li D, Sun Y, Jin L, et al
    Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
    J Med Virol. 2023;95:e28756.
    >> Share

  256. CHUANG MH, Wu JY, Liu TH, Hsu WH, et al
    Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection.
    J Med Virol. 2023;95:e28750.
    >> Share

  257. QUDUS MS, Tian M, Sirajuddin S, Liu S, et al
    The roles of critical pro-inflammatory cytokines in the drive of cytokine storm during SARS-CoV-2 infection.
    J Med Virol. 2023;95:e28751.
    >> Share

  258. TIAN F, Chen Z, Feng Q
    Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28732.
    >> Share

  259. SIMADIBRATA DM, Lesmana E, Pratama MIA, Annisa NG, et al
    Gastrointestinal Symptoms of Monkeypox Infection: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28709.
    >> Share

    March 2023
  260. SCARPA F, Giovanetti M, Azzena I, Locci C, et al
    Genome-based survey of the SARS-CoV-2 BF.7 variant from Asia.
    J Med Virol. 2023 Mar 31. doi: 10.1002/jmv.28714.
    >> Share

  261. LUO G
    Enhancement of SARS-CoV-2 infection and growth by an ACE2-specific monoclonal antibody.
    J Med Virol. 2023 Mar 28. doi: 10.1002/jmv.28711.
    >> Share

  262. ZHENG XQ, Xu QY, Xie L, He Y, et al
    Response and Duration of Serum Anti-SARS-CoV-2 Antibodies Induced by the Third Dose of an Inactivated Vaccine: A Prospective Longitudinal Cohort Study at 21 Serial Time Points over 641 Days.
    J Med Virol. 2023 Mar 25. doi: 10.1002/jmv.28703.
    >> Share

  263. ZHANG Z, Shao S, Liu X, Tong Z, et al
    Effect and safety of mesenchymal stem cells for patients with COVID-19: systematic review and meta-analysis with trial sequential analysis.
    J Med Virol. 2023 Mar 25. doi: 10.1002/jmv.28702.
    >> Share

  264. BARANOVA A, Cao H, Zhang F
    Causal associations and shared genetics between hypertension and COVID-19.
    J Med Virol. 2023 Mar 23. doi: 10.1002/jmv.28698.
    >> Share

  265. ADEN D, Zaheer S, Kumar R, Ranga S, et al
    Monkeypox (Mpox) outbreak during COVID-19 pandemic - Past and the future.
    J Med Virol. 2023 Mar 23. doi: 10.1002/jmv.28701.
    >> Share

  266. MANNAN A, Hoque MN, Noyon SH, Hamidullah Mehedi HM, et al
    SARS-CoV-2 infection alters the gut microbiome in diabetes patients: A cross-sectional study from Bangladesh.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28691.
    >> Share

  267. CHANG HC, Gau SY
    Colchicine and risk of COVID-19-associated hospitalization.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28690.
    >> Share

  268. CHEN Z, Huang T, He T, Zha G, et al
    Humoral responses after primary and booster SARS-CoV-2 inactivated vaccination in patients with chronic hepatitis B virus infection: a longitudinal observational study.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28695.
    >> Share

  269. CHEUNG AKL, Lu Y, Zhu Y, Fung TY, et al
    Consistent neutralization of circulating omicron sub-variants by hybrid immunity up to 6 months after booster vaccination.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28694.
    >> Share

  270. MAI W, Ren Y, Tian X, Al-Mahdi AY, et al
    Comparison of Common Human Respiratory Pathogens Among Hospitalized Children aged
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28692.
    >> Share

  271. DA SILVA AS, Campos GM, Giovanetti M, Zucherato VS, et al
    VIRAL METAGENOMICS UNVEILS MW (MALAWI) POLYOMAVIRUS INFECTION IN BRAZILIAN PEDIATRIC PATIENTS WITH ACUTE RESPIRATORY DISEASE.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28688.
    >> Share

  272. MAHROUM N, Elsalti A, Shoenfeld Y
    Commentary: Herpes simplex virus and SLE: though uncommon yet with significant implications.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28689.
    >> Share

  273. ZHANG Y, Lu M, Thongpan I, Xu J, et al
    Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARS-CoV-2 infection.
    J Med Virol. 2023 Mar 20. doi: 10.1002/jmv.28687.
    >> Share

  274. BOJKOVA D, Bechtel M, Rothenburger T, Kandler JD, et al
    Omicron-induced interferon signalling prevents influenza A H1N1 and H5N1 virus infection.
    J Med Virol. 2023 Mar 20. doi: 10.1002/jmv.28686.
    >> Share

  275. BIANCONI V, Mannarino MR, Cosentini E, Figorilli F, et al
    The impact of statin therapy on in-hospital prognosis and endothelial function of patients at high-to-very high cardiovascular risk admitted for COVID-19: Statins, endothelial function, and COVID-19 outcomes.
    J Med Virol. 2023 Mar 17. doi: 10.1002/jmv.28678.
    >> Share

  276. GARCIA-PEREZ J, Bermejo M, Ramirez-Garcia A, Torre Tarazona HE, et al
    Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern.
    J Med Virol. 2023 Mar 17. doi: 10.1002/jmv.28679.
    >> Share

  277. DENG J, Zheng SN, Xiao Y, Nan ML, et al
    SARS-CoV-2 NSP8 suppresses type I and III IFN responses by modulating the RIG-I/MDA5, TRIF, and STING signaling pathways.
    J Med Virol. 2023 Mar 17. doi: 10.1002/jmv.28680.
    >> Share

  278. KWON HJ, Zhang J, Kosikova M, Tang W, et al
    Distinct In Vitro and In Vivo Neutralization Profiles of Monoclonal Antibodies Elicited by the Receptor Binding Domain of the Ancestral SARS-CoV-2.
    J Med Virol. 2023 Mar 14. doi: 10.1002/jmv.28673.
    >> Share

  279. YU D, Zhao ZY, Yang YL, Qin Y, et al
    The origin and evolution of emerged swine acute diarrhea syndrome coronavirus with zoonotic potential.
    J Med Virol. 2023 Mar 14. doi: 10.1002/jmv.28672.
    >> Share

  280. FAN Z, Ruan Z, Liuzhi, Guo B, et al
    Causal association of the brain structure with the susceptibility, hospitalisation, and severity of COVID-19: A large-scale genetic correlation study.
    J Med Virol. 2023 Mar 13. doi: 10.1002/jmv.28651.
    >> Share

  281. KAN Q, Lin X, Li T, Ke X, et al
    A novel mAb broadly neutralizes SARS-CoV-2 VOCs in vitro and in vivo, including the Omicron variants.
    J Med Virol. 2023 Mar 13. doi: 10.1002/jmv.28657.
    >> Share

  282. UYGUR A, Sayili U
    Letter to the Editor: The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer.
    J Med Virol. 2023 Mar 11. doi: 10.1002/jmv.28664.
    >> Share

  283. MAZZITELLI M, Trunfio M, Sasset L, Scaglione V, et al
    Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: a real-life cohort study.
    J Med Virol. 2023 Mar 11. doi: 10.1002/jmv.28660.
    >> Share

  284. GAO L, Gao Y, Han K, Wang Z, et al
    FBXO11 amplifies type I interferon signaling to exert antiviral effects by facilitating the assemble of TRAF3-TBK1-IRF3 complex.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28655.
    >> Share

  285. JIA T, Wu Y, Liao G, Lei Y, et al
    Stable and durable antibody responses in SARS-recovered donors vaccinated with inactivated SARS-CoV-2 vaccine.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28662.
    >> Share

  286. KELLER K, Sagoschen I, Konstantinides S, Gori T, et al
    Incidence and risk factors of myocarditis in hospitalized patients with COVID-19.
    J Med Virol. 2023 Mar 9. doi: 10.1002/jmv.28646.
    >> Share

  287. GUO Z, Zhao S, Mok CKP, So RTY, et al
    Comparing the incubation period, serial interval, and infectiousness profile between SARS-CoV-2 Omicron and Delta variants.
    J Med Virol. 2023 Mar 9. doi: 10.1002/jmv.28648.
    >> Share

  288. XIA S, Jiao F, Wang L, Yu X, et al
    SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28641.
    >> Share

  289. YI X, Wang Y, Li Q, Li X, et al
    Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines.
    J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28642.
    >> Share

  290. CORMA-GOMEZ A, Fernandez-Fuertes M, Vinuela L, Dominguez C, et al
    Reduced neutralizing antibody response to SARS-CoV-2 vaccine booster dose in people living with HIV with severe immunosuppression.
    J Med Virol. 2023 Mar 6. doi: 10.1002/jmv.28602.
    >> Share

  291. LY H
    SARS-CoV-2 infection of kidney tissues in some severe and fatal cases of COVID-19.
    J Med Virol. 2023 Mar 6. doi: 10.1002/jmv.28636.
    >> Share

  292. KUITUNEN I
    No signs of "tripledemic" in Finnish children.
    J Med Virol. 2023 Mar 2. doi: 10.1002/jmv.28631.
    >> Share

  293. WANG W, Qu Y, Wang X, Xiao MZX, et al
    Genetic variety of ORF3a shapes SARS-CoV-2 fitness through modulation of lipid droplet.
    J Med Virol. 2023 Mar 2. doi: 10.1002/jmv.28630.
    >> Share

  294. KIM D, Kim J, An S, Kim M, et al
    In vitro and in vivo suppression of SARS-CoV-2 replication by a modified, short, cell-penetrating peptide targeting the C-terminal domain of the viral spike protein.
    J Med Virol. 2023 Mar 1. doi: 10.1002/jmv.28626.
    >> Share

  295. SAHIN A, Karadag-Oncel E, Buyuksen O, Ekemen-Keles Y, et al
    The diversity in the clinical features of children hospitalized with COVID-19 during the nonvariant, Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529) variant periods of SARS CoV-2: Caution for neurological symptoms in Omicron variant.
    J Med Virol. 2023 Mar 1. doi: 10.1002/jmv.28628.
    >> Share

    February 2023
  296. SCARPA F, Sanna D, Azzena I, Casu M, et al
    Genome-based comparison between the recombinant SARS-CoV-2 XBB and its parental lineages.
    J Med Virol. 2023 Feb 28. doi: 10.1002/jmv.28625.
    >> Share

  297. ZHANG J, Yang W, Huang F, Zhang K, et al
    Effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants: a systematic review and meta-analysis.
    J Med Virol. 2023 Feb 28. doi: 10.1002/jmv.28623.
    >> Share

  298. HUANG PY, Liu TH, Wu JY, Tsai YW, et al
    Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials.
    J Med Virol. 2023 Feb 27. doi: 10.1002/jmv.28621.
    >> Share

  299. LEE AR, Kweon YC, Lee SM, Park CY, et al
    Human coronavirus 3CL proteases cleave Septins and disrupt Hedgehog signaling, causing ciliary dysfunction.
    J Med Virol. 2023 Feb 24. doi: 10.1002/jmv.28618.
    >> Share

  300. CHEN JM, Gong HY, Chen RX, Liu ST, et al
    Features and significance of the recent enormous COVID-19 epidemic in China.
    J Med Virol. 2023 Feb 24. doi: 10.1002/jmv.28616.
    >> Share

  301. FENG Z, Huo D, Cui S, Lvy B, et al
    Epidemiological features, genomic characteristics, and origin tracing of the COVID-19 outbreaks in Beijing from January to September 2022.
    J Med Virol. 2023 Feb 24. doi: 10.1002/jmv.28613.
    >> Share

  302. CHEN Z, Du R, Cooper L, Achi JG, et al
    Sulforaphane is a reversible covalent inhibitor of 3-chymotrypsin-like protease of SARS-CoV-2.
    J Med Virol. 2023 Feb 24. doi: 10.1002/jmv.28609.
    >> Share

  303. TAKAHASHI K, Saito M, Sekizuka T, Itokawa K, et al
    Emergence of BS.1 and BS.1.1, highly mutated new SARS-CoV-2 Omicron variants.
    J Med Virol. 2023 Feb 24. doi: 10.1002/jmv.28615.
    >> Share

  304. ZHANG S, Ju J, Yang F, Zheng C, et al
    Ocular Tropism of SARS-CoV-2 Infection.
    J Med Virol. 2023 Feb 23. doi: 10.1002/jmv.28594.
    >> Share

  305. JAMAATI H, Karimi S, Ghorbani F, Panahi Y, et al
    Effectiveness of Different Vaccine Platforms in Reducing Mortality and Length of ICU Stay in Severe and Critical Cases of COVID-19 in the Omicron Variant Era: A National Cohort Study in Iran.
    J Med Virol. 2023 Feb 23. doi: 10.1002/jmv.28607.
    >> Share

  306. WANG Y, Shi L, Liu D, Mao Y, et al
    Changes in Epstein-Barr virus infections in the children before and after the COVID-19 pandemic in Zhengzhou, China.
    J Med Virol. 2023 Feb 23. doi: 10.1002/jmv.28597.
    >> Share

  307. BRANDA F, Scarpa F, Ciccozzi M, Maruotti A, et al
    Is a new COVID-19 wave coming from China due to an unknown variant of concern? Keep calm and look at the data.
    J Med Virol. 2023 Feb 23. doi: 10.1002/jmv.28601.
    >> Share

  308. CHEN Y, Xue Y, Yang J
    Gilteritinib: Repurposing of AXL-targeting kinase inhibitors against COVID-19.
    J Med Virol. 2023 Feb 21. doi: 10.1002/jmv.28592.
    >> Share

  309. RECTOR A, Bloemen M, Thijssen M, Delang L, et al
    Monitoring of SARS-CoV-2 concentration and circulation of variants of concern in wastewater of Leuven, Belgium.
    J Med Virol. 2023 Feb 17. doi: 10.1002/jmv.28587.
    >> Share

  310. ZHU Z, Chen X, Wang C, Zhang S, et al
    An integrated strategy to identify COVID-19 causal genes and characteristics represented by LRRC37A2.
    J Med Virol. 2023 Feb 16. doi: 10.1002/jmv.28585.
    >> Share

  311. GERMANO MJ, Giai C, Cargnelutti DE, Colombo MI, et al
    Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
    J Med Virol. 2023 Feb 16. doi: 10.1002/jmv.28584.
    >> Share

  312. STICH M, Benning L, Speer C, Garbade SF, et al
    Live-virus neutralization of the omicron variant in children and adults 14 months after SARS-CoV-2 wild-type infection.
    J Med Virol. 2023 Feb 16. doi: 10.1002/jmv.28582.
    >> Share

  313. LIN Z, Sun L, Li L, Jiang S, et al
    Nasal mucosa is much more susceptible than oral mucosa to infection of SARS-CoV-2 Omicron subvariants: wearing nasal masks where facial masks cannot be used.
    J Med Virol. 2023 Feb 13. doi: 10.1002/jmv.28577.
    >> Share

  314. RZYMSKI P, Szuster-Ciesielska A, Dzieciatkowski T, Gwenzi W, et al
    mRNA vaccines: The future of prevention of viral infections?
    J Med Virol. 2023 Feb 10. doi: 10.1002/jmv.28572.
    >> Share

  315. YAO M, Huang X, Guo Y, Zhao JV, et al
    Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with COVID-19 outcomes: genome-wide cross trait analysis and bi-directional Mendelian randomization study.
    J Med Virol. 2023 Feb 10. doi: 10.1002/jmv.28570.
    >> Share

  316. RADOVIC S, Meng W, Chen L, Paniz Mondolfi AE, et al
    SARS-CoV-2 infection of kidney tissues from severe COVID-19 patients.
    J Med Virol. 2023 Feb 9. doi: 10.1002/jmv.28566.
    >> Share

  317. NICOT F, Tremeaux P, Latour J, Carcenac R, et al
    WHOLE-GENOME SINGLE MOLECULE REAL-TIME SEQUENCING OF SARS-CoV-2 OMICRON.
    J Med Virol. 2023 Feb 9. doi: 10.1002/jmv.28564.
    >> Share

  318. WANG X, Yang Y, Song Z, Wang Y, et al
    Concerns on Bebtelovimab (LY-CoV1404) used to neutralize Omicron subvariants.
    J Med Virol. 2023 Feb 9. doi: 10.1002/jmv.28565.
    >> Share

  319. CRADDOCK V, Mahajan A, Spikes L, Krishnamachary B, et al
    Persistent Circulation of Soluble and Extracellular vesicle-linked Spike Protein in Individuals with Post-Acute Sequelae of COVID-19.
    J Med Virol. 2023 Feb 9. doi: 10.1002/jmv.28568.
    >> Share

  320. ZHANG T, Wang Z, Yang J, Xu X, et al
    Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern.
    J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28563.
    >> Share

  321. DUTTA D, Ghosh A, Dutta C, Sukla S, et al
    Cross reactivity of SARS-CoV-2 with other pathogens, especially dengue virus: A historical perspective.
    J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28557.
    >> Share

  322. KANG CK, Kim MG, Park SW, Kim YW, et al
    Comparable humoral and cellular immunity against Omicron variant BA.4/5 of once-boosted BA.1/2 convalescents and twice-boosted COVID-19-naive individuals.
    J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28558.
    >> Share

  323. DENG J, Zheng Y, Zheng SN, Nan ML, et al
    SARS-CoV-2 NSP7 inhibits type I and III IFN production by targeting the RIG-I/MDA5, TRIF, and STING signaling pathways.
    J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28561.
    >> Share

  324. CHEN J, Cheng X, Xu Y, Shi T, et al
    Analysis on the Physiological Changes of Residents Before and During the COVID-19 Pandemic: A Cross-Sectional Study.
    J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28562.
    >> Share

  325. TONYALI A, Karacetin G, Yesilkaya C, Arik FNT, et al
    Appearance of extrapyramidal symptoms in adolescent psychiatry patients during Covid-19 infection.
    J Med Virol. 2023 Feb 4. doi: 10.1002/jmv.28556.
    >> Share

  326. GUO Y, Guo Y, Zhang Y, Li F, et al
    Factors Affecting Prolonged SARS-CoV-2 Infection and Development and Validation of Predictive Nomograms.
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28550.
    >> Share

  327. WEI B, Liu Y, Li H, Peng Y, et al
    Impact of alcohol consumption on COVID-19 severity: A systematic review and meta-analysis.
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28547.
    >> Share

  328. AKIF A, Bhuiyan MA, Islam MR
    SARS-COV-2 omicron subvariant BF.7 is again triggering the Covid fear: What we need to know and what we should do?
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28551.
    >> Share

  329. KHAN A, Imran K, Zhu G, Ji J, et al
    Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28542.
    >> Share

  330. TORRE-TARAZONA E, Gonzalez-Robles A, Cascajero A, Jimenez P, et al
    Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28543.
    >> Share

  331. BAIOCCHI GC, Vojdani A, Rosenberg AZ, Vojdani E, et al
    Cross-sectional analysis reveals autoantibody signatures associated with COVID-19 severity.
    J Med Virol. 2023 Feb 1. doi: 10.1002/jmv.28538.
    >> Share

  332. WANG X, He X, Jiang S, Fu Z, et al
    Limited enhancement of antibody and B-cell responses to prototype booster vaccination following SARS-CoV-2 Delta breakthrough infection.
    J Med Virol. 2023 Feb 1. doi: 10.1002/jmv.28540.
    >> Share

  333. KORSUN N, Trifonova I, Dobrinov V, Madzharova I, et al
    Low prevalence of influenza viruses and predominance of A(H3N2) virus with respect to SARS-CoV-2 during the 2021-2022 season in Bulgaria.
    J Med Virol. 2023;95:e28489.
    >> Share

  334. SKINNER JP, Moran LV
    Persistent effects of COVID-19 in patients hospitalized during the first wave of the pandemic: The impact of persistent fatigue on quality of life in a cross-sectional study.
    J Med Virol. 2023;95:e28491.
    >> Share

  335. KUMARI D, Singh Y, Singh S, Dogra V, et al
    "Mitochondrial pathogenic mutations and metabolic alterations associated with COVID-19 disease severity".
    J Med Virol. 2023;95:e28553.
    >> Share

    January 2023
  336. CHEN Z, Li J, Zheng J, Jin Y, et al
    Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection.
    J Med Virol. 2023 Jan 31. doi: 10.1002/jmv.28539.
    >> Share

  337. HEYDECKE A, Gullsby K
    Evaluation of the performance of a rapid antigen test (Roche) for COVID-19 diagnosis in an emergency setting in Sweden.
    J Med Virol. 2023 Jan 30. doi: 10.1002/jmv.28537.
    >> Share

  338. QUAN NK, Thien DH, Huy NT
    Detect and suppress future zoonotic-derived outbreaks: A lesson from last two decades.
    J Med Virol. 2023 Jan 30. doi: 10.1002/jmv.28530.
    >> Share

  339. SUN C, Yau V, Uy JPN, Lowe S, et al
    Does viral inoculum play a role in disease severity in COVID-19?
    J Med Virol. 2023 Jan 27. doi: 10.1002/jmv.28532.
    >> Share

  340. WANG J, Yin X, Yu L, Cheng W, et al
    Delayed cutaneous hypersensitivity reactions following the use of infliximab or adalimumab in patients with coronavirus disease 2019.
    J Med Virol. 2023 Jan 26. doi: 10.1002/jmv.28518.
    >> Share

  341. BONGIOVANNI M, Barilaro G, Bini F
    Twelve-month clinical, functional and radiological outcomes in patients hospitalized for SARS-CoV-2 pneumonia.
    J Med Virol. 2023 Jan 25. doi: 10.1002/jmv.28524.
    >> Share

  342. SHIRAZ R, Tripathi S
    Enhanced recombination among omicron subvariants of SARS-CoV-2 contributes to viral immune escape.
    J Med Virol. 2023 Jan 24. doi: 10.1002/jmv.28519.
    >> Share

  343. KIM K, Cho K, Song J, Rahmati M, et al
    The case fatality rate of COVID-19 during the Delta and the Omicron epidemic phase: A meta-analysis.
    J Med Virol. 2023 Jan 24. doi: 10.1002/jmv.28522.
    >> Share

  344. SHEN F, Yang CX, Lu Y, Zhang M, et al
    Significant neutralizing escapes of Omicron and its sub-lineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
    J Med Virol. 2023 Jan 21. doi: 10.1002/jmv.28516.
    >> Share

  345. ROBERTO P, Cinti L, Napoli A, Paesani D, et al
    Torque teno virus (TTV): a gentle spy virus of immune status, predictive marker of seroconversion to COVID-19 vaccine in kidney and lung transplant recipients.
    J Med Virol. 2023 Jan 20. doi: 10.1002/jmv.28512.
    >> Share

  346. LIAN XY, Xi L, Zhang ZS, Yang LL, et al
    Impact of air pollutants on influenza-like illness outpatient visits under COVID-19 pandemic in the sub-center of Beijing, China.
    J Med Virol. 2023 Jan 20. doi: 10.1002/jmv.28514.
    >> Share

  347. ZHAO Y, Du J, Li Z, Wu Y, et al
    It Is Time to Improve the Acceptance of COVID-19 Vaccines Among People with Chronic Diseases: A Systematic Review and Meta-analysis.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28509.
    >> Share

  348. HASSEBROEK AM, Sooryanarain H, Lynn Heffron C, Hawks SA, et al
    A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28503.
    >> Share

  349. HARADA KH, Phosri A
    A protocol of trial of ivermectin in COVID-19 treatment critically changed after its completion.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28505.
    >> Share

  350. MATIC S, Milovanovic D, Mijailovic Z, Djurdjevic P, et al
    IFNL3/4 polymorphisms as a two-edged sword: an association with COVID-19 outcome.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28506.
    >> Share

  351. ABD-ELSALAM S, Medhat MA, Ramadan HK, Soliman S, et al
    Reply to letter to the editor.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28502.
    >> Share

  352. PAN J, Yang S, Chen X, Che X, et al
    Two-year impact of COVID-19 pandemic on hospitalized patients with skin diseases in China.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28511.
    >> Share

  353. ERDIK B
    Covid Associated Immune Dysfunction (CAID) Leading to Increased Pediatric Hospitalizations.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28508.
    >> Share

  354. QI T, Jin Y, Wang H, Liao Y, et al
    Nirmatrelvir-ritonavir Therapy and COVID-19 Vaccination Improve Clinical Outcomes of SARS-CoV-2 Omicron Variant Infection.
    J Med Virol. 2023 Jan 18. doi: 10.1002/jmv.28497.
    >> Share

  355. MORALES-ORTEGA A, Farfan-Sedano AI, Martin-Lopez JVS, Escriba-Barcena A, et al
    Baricitinib or imatinib in hospitalized COVID-19 patients: results from COVINIB, an exploratory randomized clinical trial.
    J Med Virol. 2023 Jan 13. doi: 10.1002/jmv.28495.
    >> Share

  356. ALDEA MS, Salgado-Barreira A, Trunk MT, Lamas MP, et al
    Colchicine and risk of hospitalisation due to COVID-19: a population-based study.
    J Med Virol. 2023 Jan 13. doi: 10.1002/jmv.28496.
    >> Share

  357. BERBER NK, Geckil AA, Altan NO, Kiran TR, et al
    Efficacy of Serum Apelin and Galectin-3 as Potential Predictors of Mortality in Severe COVID-19 Patients.
    J Med Virol. 2023 Jan 12. doi: 10.1002/jmv.28494.
    >> Share

  358. KIM SH, Baek JY, Han M, Lee M, et al
    A decrease in the incidence of encephalitis in South Korea during the COVID-19 pandemic: A nationwide study between 2010 and 2021.
    J Med Virol. 2023 Jan 11. doi: 10.1002/jmv.28490.
    >> Share

  359. XIONG N, Sun Q
    How does SARS-CoV-2 Infection impact on immunity, procession and treatment of Pan Cancers.
    J Med Virol. 2023 Jan 10. doi: 10.1002/jmv.28487.
    >> Share

  360. YADAV PD, Kumar S, Agarwal K, Jain M, et al
    Needle-free injection system delivery of ZyCoV-D DNA vaccine demonstrated improved immunogenicity and protective efficacy in Rhesus macaques against SARS-CoV-2.
    J Med Virol. 2023 Jan 10. doi: 10.1002/jmv.28484.
    >> Share

  361. WANG M, Huang L
    Letter to the Editor Regarding "Effects of inactivated SARS-CoV-2 vaccination on male fertility: a retrospective cohort study".
    J Med Virol. 2023 Jan 10. doi: 10.1002/jmv.28486.
    >> Share

  362. KRISHNAMOORTHY P, Raj AS, Kumar H
    Machine learning-driven blood transcriptome-based discovery of SARS-CoV-2 specific severity biomarkers.
    J Med Virol. 2023 Jan 10. doi: 10.1002/jmv.28488.
    >> Share

  363. HUANG HC, Wang SH, Fang GC, Chou WC, et al
    Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion.
    J Med Virol. 2023 Jan 7. doi: 10.1002/jmv.28478.
    >> Share

  364. TENG L, Song X, Zhang M, Han Y, et al
    The pattern of cytokines expression and dynamic changes of renal function at 6 months in patients with Omicron COVID-19.
    J Med Virol. 2023 Jan 7. doi: 10.1002/jmv.28477.
    >> Share

  365. FARIAS JP, Pinheiro JR, Andreata-Santos R, Fogaca MMC, et al
    The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS-CoV-2 variant.
    J Med Virol. 2023 Jan 7. doi: 10.1002/jmv.28481.
    >> Share

  366. CHEEMA HA, Jafar U, Sohail A, Shahid A, et al
    Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: a systematic review and meta-analysis.
    J Med Virol. 2023 Jan 6. doi: 10.1002/jmv.28471.
    >> Share

  367. LEI Z, Zhu L, Pan P, Ruan Z, et al
    A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants.
    J Med Virol. 2023 Jan 6. doi: 10.1002/jmv.28475.
    >> Share

  368. LI X, Yin W, Li A, Li D, et al
    ACE2 PET to Reveal the Dynamic Patterns of ACE2 Recovery in an Infection Model with Pseudo Corona Virus.
    J Med Virol. 2023 Jan 6. doi: 10.1002/jmv.28470.
    >> Share

  369. CHUNG H, Ko H, Lee H, Yon DK, et al
    Development and validation of a deep learning model to diagnose COVID-19 using time-series heart rate values before the onset of symptoms.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28462.
    >> Share

  370. KWON R, Koo MJ, Lee SW, Choi YS, et al
    National trends in physical activity among adolescents in South Korea before and during the COVID-19 pandemic, 2009-2021.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28456.
    >> Share

  371. MERZA MA, Almufty HB, Younis HA, Rasool SO, et al
    Memory impairment among recovered COVID-19 patients: the prevalence and risk factors, a retrospective cohort study.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28459.
    >> Share

  372. VAEZI M, Ravanshad S, Rad MA, Zarrinfar H, et al
    The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID-19 patients: A randomized placebo-controlled trial.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28463.
    >> Share

  373. KOH LP, Chua SL, Vasoo S, Toh MPHS, et al
    Real-World Effectiveness of Sotrovimab and Remdesivir for Early Treatment of High-Risk Hospitalized COVID-19 Patients - a Propensity Score Adjusted Retrospective Cohort Study.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28460.
    >> Share

  374. TOWNSEND JP, Hassler HB, Dornburg A
    Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28461.
    >> Share

  375. PRADO CAS, Fonseca DLM, Singh Y, Filgueiras IS, et al
    Title: Integrative systems immunology uncovers molecular networks of the cell cycle that stratify COVID-19 severity.
    J Med Virol. 2023 Jan 4. doi: 10.1002/jmv.28450.
    >> Share

  376. LIU X, Du Z, Wang J, Wang Q, et al
    Association between trans fatty acids and COVID-19: a multivariate Mendelian randomization study.
    J Med Virol. 2023 Jan 4. doi: 10.1002/jmv.28455.
    >> Share

  377. KIRAZ A, Sezer O, Alemdar A, Canbek S, et al
    Contribution of genotypes in Prothrombin and Factor V Leiden to COVID-19 and disease severity in patients at high risk for hereditary thrombophilia.
    J Med Virol. 2023 Jan 4. doi: 10.1002/jmv.28457.
    >> Share

  378. BELTRAN DM, Villamil Osorio M, Fonseca SLG, Restrepo S, et al
    PREDICTORS OF SEVERITY IN SEVERE RESPIRATORY INFECTION IN CHILDREN WITH COVID-19 RESPIRATORY INFECTION IN A DEVELOPING COUNTRY.
    J Med Virol. 2023 Jan 3. doi: 10.1002/jmv.28453.
    >> Share

  379. FOCOSI D, Maggi F, Shoham S, Casadevall A, et al
    Discriminating endogenous vaccine-elicited anti-Spike antibody responses from exogenous anti-Spike monoclonal antibodies: The case of Evusheld.
    J Med Virol. 2023;95:e28277.
    >> Share

  380. LAI CJ, Kim D, Kang S, Li K, et al
    Viral codon optimization on SARS-CoV-2 Spike boosts immunity in the development of COVID-19 mRNA vaccines.
    J Med Virol. 2023;95:e29183.
    >> Share

    December 2022
  381. KIM JG, Zhang A, Rauseo AM, Goss CW, et al
    The salivary and nasopharyngeal microbiomes are associated with SARS-CoV-2 infection and disease severity.
    J Med Virol. 2022 Dec 30. doi: 10.1002/jmv.28445.
    >> Share

  382. LUO J, Zhang J, Tang HT, Wong HK, et al
    Weekly Symptom Profiles of Non-hospitalized Individuals Infected with SARS-CoV-2 During the Omicron Outbreak in Hong Kong: A Retrospective Observational Study from a Telemedicine Centre.
    J Med Virol. 2022 Dec 30. doi: 10.1002/jmv.28447.
    >> Share

  383. WANG Y, Zhao D, Liu X, Chen X, et al
    Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 omicron variants.
    J Med Virol. 2022 Dec 29. doi: 10.1002/jmv.28443.
    >> Share

  384. ACOSTA N, Bautista MA, Waddell BJ, Du K, et al
    Surveillance for SARS-CoV-2 and its variants in wastewater of tertiary care hospitals correlates with increasing case burden and outbreaks.
    J Med Virol. 2022 Dec 29. doi: 10.1002/jmv.28442.
    >> Share

  385. HOFFMANN AT, da Silva MS, Gularte JS, Pasqualotto AC, et al
    Dynamics of nosocomial SARS-CoV-2 transmissions: facing the challenge of variants of concern in a Brazilian reference hospital.
    J Med Virol. 2022 Dec 29. doi: 10.1002/jmv.28446.
    >> Share

  386. HUANG J, Yang X, Ren L, Jiang W, et al
    A novel, ultrafast, ultrasensitive diagnosis platform for the detection of SARS-COV-2 using restriction endonuclease-mediated reverse transcription multiple cross displacement amplification.
    J Med Virol. 2022 Dec 29. doi: 10.1002/jmv.28444.
    >> Share

  387. AMANI B, Amani B
    Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19 : a rapid review and meta-analysis.
    J Med Virol. 2022 Dec 28. doi: 10.1002/jmv.28441.
    >> Share

  388. LI S, Wu J, Jiang W, He H, et al
    Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies.
    J Med Virol. 2022 Dec 27. doi: 10.1002/jmv.28440.
    >> Share

  389. ZHANG GF, Meng W, Chen L, Ding L, et al
    Infectivity of pseudotyped SARS-CoV-2 variants of concern in different human cell types and inhibitory effects of recombinant spike protein and entry-related cellular factors.
    J Med Virol. 2022 Dec 27. doi: 10.1002/jmv.28437.
    >> Share

  390. LI T, Li X, Chen N, Yang J, et al
    Influence of the COVID-19 Pandemic on the Vitamin D Status of Children: A Cross-Sectional Study.
    J Med Virol. 2022 Dec 27. doi: 10.1002/jmv.28438.
    >> Share

  391. ZARUR-TORRALVO S, Stand-Nino I, Florez-Garcia V, Mendoza H, et al
    Viruses Responsible for Acute Respiratory Infections Before (2016-2019) and During (2021) Circulation of the SARS-CoV-2 virus in Pediatric Patients in a Reference Center at Barranquilla Colombia: A Pattern Analysis.
    J Med Virol. 2022 Dec 27. doi: 10.1002/jmv.28439.
    >> Share

  392. MACHADO TL, Santos AC, Azamor T, Vieira da Silva AM, et al
    CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID-19 therapy.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28427.
    >> Share

  393. LAI CC, Hsueh PR
    Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28430.
    >> Share

  394. BARANOVA A, Cao H, Teng S, Su KP, et al
    Shared genetics and causal associations between COVID-19 and multiple sclerosis.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28431.
    >> Share

  395. ZHAN H, Gao H, Liu Y, Zhang X, et al
    Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28428.
    >> Share

  396. LI H, Cai D, Jiang D, Li X, et al
    Risk of waning humoral responses after inactivated or subunit recombinant SARS-CoV-2 vaccination in patients with chronic diseases: Findings from a prospective observational study in China.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28434.
    >> Share

  397. ZHAO Y, Zhao Y, Ai A, Jin L, et al
    Association of inactivated COVID-19 vaccination with in vitro fertilization and early pregnancy outcomes.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28432.
    >> Share

  398. LAI CC, Hsu CK, Hsueh SC, Yen MY, et al
    Multisystem inflammatory syndrome in adults: Characteristics, treatment, and outcomes.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28426.
    >> Share

  399. RUSSELL SL, Klaver BRA, Harrigan SP, Kamelian K, et al
    Clinical severity of Omicron sub-variants BA.1, BA.2 and BA.5 in a population-based cohort study in British Columbia, Canada.
    J Med Virol. 2022 Dec 22. doi: 10.1002/jmv.28423.
    >> Share

  400. MAHALINGAM G, Periyasami Y, Arjunan P, Subaschandrabose RK, et al
    Omicron infection increases IgG binding to spike protein of predecessor variants.
    J Med Virol. 2022 Dec 22. doi: 10.1002/jmv.28419.
    >> Share

  401. WANG Y, Chen X, Liu X, Zhao D, et al
    Nirmatrelvir-ritonavir might only be effective in elderly patients.
    J Med Virol. 2022 Dec 21. doi: 10.1002/jmv.28418.
    >> Share

  402. BANERJEE A, Mazumder A, Roy J, Das J, et al
    Emergence of a unique SARS-CoV-2 Delta sub-cluster harboring a constellation of co-appearing non-Spike mutations.
    J Med Virol. 2022 Dec 21. doi: 10.1002/jmv.28413.
    >> Share

  403. FOURIE E, Sijm YE, Badoux P, Merelle ME, et al
    High Detection Rate of Viral Pathogens in Nasal Discharge in Children Aged 0 till 5 Years.
    J Med Virol. 2022 Dec 21. doi: 10.1002/jmv.28415.
    >> Share

  404. PRAKASHAN D, Shrikrishna NS, Byakodi M, Nagamani K, et al
    Gold nanoparticle conjugate-based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS CoV-2 in clinical samples using smartphone-based application.
    J Med Virol. 2022 Dec 21. doi: 10.1002/jmv.28416.
    >> Share

  405. ALZAHRANI MM, Bamashmous S, Alkharobi H, Alghamdi A, et al
    Mouth Rinses Efficacy on Salivary SARS-CoV-2 Viral Load: A Randomized Clinical Trial.
    J Med Virol. 2022 Dec 17. doi: 10.1002/jmv.28412.
    >> Share

  406. JIANG ML, Xu YP, Wu H, Zhu RN, et al
    Changes in endemic patterns of respiratory syncytial virus infection in pediatric patients under the pressure of nonpharmaceutical interventions for COVID-19 in Beijing, China.
    J Med Virol. 2022 Dec 16. doi: 10.1002/jmv.28411.
    >> Share

  407. WANG Q, Ye SB, Zhou ZJ, Song AL, et al
    Key mutations in the spike protein of SARS-CoV-2 affecting neutralization resistance and viral internalization.
    J Med Virol. 2022 Dec 15. doi: 10.1002/jmv.28407.
    >> Share

  408. ZHOU C, Wu A, Ye S, Zhou Z, et al
    Possible transmission of COVID-19 epidemic by a dog as a passive mechanical carrier of SARS-CoV-2, Chongqing, China, 2022.
    J Med Virol. 2022 Dec 15. doi: 10.1002/jmv.28408.
    >> Share

  409. LI X, Li T, Chen N, Wang X, et al
    Influence of COVID-19 pandemic on inhaled allergens in children with allergic diseases, Henan, China.
    J Med Virol. 2022 Dec 15. doi: 10.1002/jmv.28409.
    >> Share

  410. ABEYWARDHANA S, Bandaranayake U, Perera DB, Premathilaka M, et al
    In silico study of SARS-CoV-2 Spike protein RBD and human ACE-2 affinity dynamics across variants and Omicron sub-variants.
    J Med Virol. 2022 Dec 15. doi: 10.1002/jmv.28406.
    >> Share

  411. VIETZEN H, Furlano PL, Traugott M, Totschnig D, et al
    The Natural Killer cell-associated rs9916629-C allele is a novel genetic risk factor for fatal COVID-19.
    J Med Virol. 2022 Dec 14. doi: 10.1002/jmv.28404.
    >> Share

  412. AKRAMI S, Montazeri EA, Saki M, Neisi N, et al
    Bacterial profiles and their antibiotic resistance background in superinfections caused by multidrug-resistant bacteria among COVID-19 ICU patients from southwest Iran.
    J Med Virol. 2022 Dec 14. doi: 10.1002/jmv.28403.
    >> Share

  413. HAYES LJ, Uri H, Bojkova D, Cinatl J Jr, et al
    Impact of the COVID-19 pandemic on the circulation of other pathogens in England.
    J Med Virol. 2022 Dec 13. doi: 10.1002/jmv.28401.
    >> Share

  414. CAMACHO J, Albert E, Zulaica J, Alvarez-Rodriguez B, et al
    A Performance Comparison of two (Electro) chemiluminescence Immunoassays for Detection and Quantitation of Serum Anti-Spike Antibodies According to SARS-CoV-2 Vaccination and Infections Status.
    J Med Virol. 2022 Dec 12. doi: 10.1002/jmv.28397.
    >> Share

  415. PANAHI Y, Ghanei M, Rahimi M, Samim A, et al
    Evaluation the efficacy and safety of N-acetylcysteine inhalation spray in controlling the symptoms of patients with COVID-19: An open-label randomized controlled clinical trial.
    J Med Virol. 2022 Dec 10. doi: 10.1002/jmv.28393.
    >> Share

  416. GOEL A, Ray A, Chavan A, Sahni S, et al
    A study on the morbid Histopathological changes in COVID-19 patients with or without comorbidities using minimally invasive tissue sampling.
    J Med Virol. 2022 Dec 8. doi: 10.1002/jmv.28384.
    >> Share

  417. YANG Q, Tang J, Cao J, Liu F, et al
    SARS-CoV-2 infection activates CREB/CBP in cellular cyclic AMP-dependent pathways.
    J Med Virol. 2022 Dec 8. doi: 10.1002/jmv.28383.
    >> Share

  418. YAN Q, Zheng W, Jiang Y, Zhou P, et al
    Transcriptomic reveals the ferroptosis features of host response in a mouse model of Zika virus infection.
    J Med Virol. 2022 Dec 8. doi: 10.1002/jmv.28386.
    >> Share

  419. RIZZO A, Foschi A, Bracchitta F, Faggion I, et al
    Persistent detection and sequencing of SARS-CoV-2 in the bloodstream of an immunocompromised patient.
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28381.
    >> Share

  420. LI M, Hao J, Jiang T, Deng W, et al
    Maternal and neonatal safety of COVID-19 vaccination during peri-pregnancy period: a prospective study.
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28378.
    >> Share

  421. WANG H, Gan M, Wu B, Zeng R, et al
    Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: a prospective cohort study.
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28380.
    >> Share

  422. LIN-WANG HT, Damiani LP, Farias EDS, Bajgelman MC, et al
    Longitudinal study comparing IgG antibodies induced by heterologous prime-boost COVID-19 vaccine.
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28379.
    >> Share

  423. ZHENG Z, Lu Y, Wang M, Luo Y, et al
    Low COVID-19 Vaccine Coverage and Guardian Acceptance Among Pediatric Transplant Recipients.
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28377.
    >> Share

  424. SCHULTHEISS C, Willscher E, Paschold L, Gottschick C, et al
    Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28364.
    >> Share

  425. KANG SW, Kim JY, Park H, Lim SY, et al
    Comparison of Secondary Attack Rate and Viable Virus Shedding between Patients with SARS-CoV-2 Delta and Omicron Variants: A Prospective Cohort Study.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28369.
    >> Share

  426. SHEN KY, Yang CH, Chen CT, Ho HM, et al
    Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28370.
    >> Share

  427. VIRSEDA-BERDICES A, Concostrina-Martinez L, Martinez-Gonzalez O, Blancas R, et al
    RELATIVE TELOMERE LENGTH IMPACT ON MORTALITY OF COVID-19: SEX DIFFERENCES.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28368.
    >> Share

  428. WOLF JM, Wolf LM, Bello GL, Maccari JG, et al
    Molecular evolution of SARS-CoV-2 from December 2019 to August 2022.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28366.
    >> Share

  429. LI J, Zheng J, Chen P, Wang B, et al
    Higher SARS-CoV-2 shedding in exhaled aerosol probably contributed to the enhanced transmissibility of Omicron BA.5 subvariant.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28365.
    >> Share

  430. PARKER M, Sawant HB, Flannery T, Tarrant R, et al
    Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28373.
    >> Share

  431. MOKHTARI MB, Samaniego V, Mokhtari MB, Ishak A, et al
    Relationship of Prior COVID-19 infection and Side Effects of Pfizer-BioNTech Vaccine: Results from a Community Hospital.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28374.
    >> Share

    November 2022
  432. FATMA B, Yohan N, Domitille C, Anne-Laure L, et al
    Early Plasma Interferon-beta Levels as a Predictive Marker of COVID-19 Severe Clinical Events in Adult Patients.
    J Med Virol. 2022 Nov 30. doi: 10.1002/jmv.28361.
    >> Share

  433. LUO D, Li T, Yang X, Ning N, et al
    The immunodominance of RBD antigen of delta variant as vaccine candidate against SARS-CoV-2 infection.
    J Med Virol. 2022 Nov 29. doi: 10.1002/jmv.28359.
    >> Share

  434. MIHAYLOVA A, Lesichkova S, Baleva M, Nikolova-Vlahova M, et al
    DURABILITY OF HUMORAL AND CELL-MEDIATED IMMUNE RESPONSE AFTER SARS-CoV-2 mRNA VACCINE ADMINISTRATION.
    J Med Virol. 2022 Nov 29. doi: 10.1002/jmv.28360.
    >> Share

  435. PARK SH, Hong SH, Kim K, Lee SW, et al
    Non-Pharmaceutical Interventions Reduce the Incidence, and Mortality of COVID-19: A Study based on the Survey from the International COVID-19 Research Network (ICRN).
    J Med Virol. 2022 Nov 29. doi: 10.1002/jmv.28354.
    >> Share

  436. PAN Y, Wang S, Liu G, Wang L, et al
    The third inactivated vaccine booster dramatically enhanced SARS-CoV-2 antibody responses and did not influence the profile of prothrombotic antibody.
    J Med Virol. 2022 Nov 28. doi: 10.1002/jmv.28356.
    >> Share

  437. GHOLAMI M, Zoughi M, Hasanzad M, Larijani B, et al
    Haplotypic variants of COVID-19 related genes are associated with blood pressure and metabolites levels.
    J Med Virol. 2022 Nov 28. doi: 10.1002/jmv.28355.
    >> Share

  438. DU M, Wang R, Yuan J, Lv X, et al
    Trends and disparities in 44 national notifiable infectious diseases in China: an analysis of national surveillance data from 2010 to 2019.
    J Med Virol. 2022 Nov 28. doi: 10.1002/jmv.28353.
    >> Share

  439. YAN H, Zhang R, Yan G, Liu Z, et al
    Production of a versatile SARS-CoV-2 main protease biosensor based on a dimerization-dependent red fluorescent protein.
    J Med Virol. 2022 Nov 24. doi: 10.1002/jmv.28342.
    >> Share

  440. LI K, Shi J, Liu X, Ward MP, et al
    Early warning signals for Omicron outbreaks in China: a retrospective study.
    J Med Virol. 2022 Nov 24. doi: 10.1002/jmv.28341.
    >> Share

  441. JIA C, Zhou Z, Pan W, Zhang P, et al
    Immune Repertoire Sequencing Reveals an Abnormal Adaptive Immune System in COVID-19 Survivors.
    J Med Virol. 2022 Nov 24. doi: 10.1002/jmv.28340.
    >> Share

  442. LIN YF, Wu X, Li Y, Bian J, et al
    Impact of combination preventative interventions on hospitalization and death under the pandemic of SARS-CoV-2 Omicron variant in China.
    J Med Virol. 2022 Nov 23. doi: 10.1002/jmv.28335.
    >> Share

  443. DONG Y, Li X, Li Z, Zhu Y, et al
    Effects of inactivated SARS-CoV-2 vaccination on male fertility: a retrospective cohort study.
    J Med Virol. 2022 Nov 22. doi: 10.1002/jmv.28329.
    >> Share

  444. TAKAKURA K, Suka M, Kajihara M, Koido S, et al
    Clinical features, therapeutic outcomes and recovery period of long COVID.
    J Med Virol. 2022 Nov 22. doi: 10.1002/jmv.28316.
    >> Share

  445. ONG CP, Ye ZW, Tang K, Liang R, et al
    Comparative analysis of SARS-CoV-2 Omicron BA.2.12.1 and BA.5.2 variants.
    J Med Virol. 2022 Nov 21. doi: 10.1002/jmv.28326.
    >> Share

  446. RAHMATI M, Koyanagi A, Banitalebi E, Yon DK, et al
    The effect of SARS-CoV-2 infection on cardiac function in post-COVID-19 survivors: A systematic review and meta-analysis.
    J Med Virol. 2022 Nov 18. doi: 10.1002/jmv.28325.
    >> Share

  447. GAO W, Li Z, Guan Q, Cui W, et al
    Characterisation and analysis of linear epitopes corresponding to SARS-CoV-2 outbreak in Jilin Province, China.
    J Med Virol. 2022 Nov 18. doi: 10.1002/jmv.28323.
    >> Share

  448. DOBROVOLNA M, Brazda V, Warner EF, Bidula S, et al
    Inverted repeats in the monkeypox virus genome are hot spots for mutation.
    J Med Virol. 2022 Nov 18:e28322. doi: 10.1002/jmv.28322.
    >> Share

  449. CHAN CC, Liaw YP
    Letter to the Editor Regarding "The clinical and bioinformatics analysis for the role of antihypertension drugs on mortality among patients with hypertension hospitalized with COVID-19".
    J Med Virol. 2022 Nov 17. doi: 10.1002/jmv.28319.
    >> Share

  450. SMITH H, Mahon A, Moss A, Rao S, et al
    SARS-CoV-2 Infection in Children Evaluated in an Ambulatory Setting During Delta and Omicron Time Periods.
    J Med Virol. 2022 Nov 17. doi: 10.1002/jmv.28318.
    >> Share

  451. ALI AM, Tofiq AM, Rostam HM, Ali KM, et al
    Reply to Letter to the Editor on disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    J Med Virol. 2022 Nov 15. doi: 10.1002/jmv.28313.
    >> Share

  452. SCHLESINGER M, McDonald C, Ahuja A, Canete CA, et al
    GLUCOSE AND MANNOSE ANALOGS INHIBIT KSHV REPLICATION BY BLOCKING N-GLYCOSYLATION AND INDUCING THE UNFOLDED PROTEIN RESPONSE.
    J Med Virol. 2022 Nov 15. doi: 10.1002/jmv.28314.
    >> Share

  453. LIN L, Deng J, Li J, Zheng L, et al
    Pathogenesis and histological changes of nephropathy associated with COVID-19.
    J Med Virol. 2022 Nov 15. doi: 10.1002/jmv.28311.
    >> Share

  454. LOU M, Huang D, Zhou Z, Shi X, et al
    DNA virus oncoprotein HPV18 E7 selectively antagonizes cGAS-STING-triggered innate immune activation.
    J Med Virol. 2022 Nov 15. doi: 10.1002/jmv.28310.
    >> Share

  455. ERGOREN MC, Akan G, Volkan E, Kandemis E, et al
    The "vaccine" hubbub: Viral load comparisons of SARS-CoV-2 Delta and Omicron variants against different vaccine-booster vaccine combinations.
    J Med Virol. 2022 Nov 14. doi: 10.1002/jmv.28309.
    >> Share

  456. ABORODE AT, Huang H, Awuah WA, Mehta A, et al
    Approaching COVID-19 with epidemiological genomic surveillance and the sustainability of biodiversity informatics in Africa.
    J Med Virol. 2022 Nov 13. doi: 10.1002/jmv.28308.
    >> Share

  457. CHEN J, Li F, Tian J, Xie X, et al
    Varicella Zoster Virus Reactivation Following COVID-19 Vaccination in patients with autoimmune inflammatory rheumatic diseases: A cross-sectional Chinese study of 318 cases.
    J Med Virol. 2022 Nov 13. doi: 10.1002/jmv.28307.
    >> Share

  458. REUSCH J, Wagenhauser I, Gabel A, Eggestein A, et al
    Influencing factors of anti-SARS-CoV-2-spike-IgG antibody titers in healthcare workers: A cross-section study.
    J Med Virol. 2022 Nov 11:e28300. doi: 10.1002/jmv.28300.
    >> Share

  459. CHIRUMBOLO S
    The widest use of paracetamol in home therapy might have actually increased the occurrence of severe forms of COVID-19 in Italy, affecting hospitalization and death rates.
    J Med Virol. 2022 Nov 11:e28301. doi: 10.1002/jmv.28301.
    >> Share

  460. YANG Y, Xing H, Zhao Y
    Transplacental transmission of SARS-CoV-2 immunoglobulin G antibody to infants from maternal COVID-19 vaccine immunization before pregnancy.
    J Med Virol. 2022 Nov 11:e28296. doi: 10.1002/jmv.28296.
    >> Share

  461. RAHMATI M, Fatemi R, Yon DK, Lee SW, et al
    The effect of adherence to high-quality dietary pattern on COVID-19 outcomes: A systematic review and meta-analysis.
    J Med Virol. 2022 Nov 11:e28298. doi: 10.1002/jmv.28298.
    >> Share

  462. YE Q, Liu H, Mao J, Shu Q, et al
    Nonpharmaceutical interventions for COVID-19 disrupt the dynamic balance between influenza A virus and human immunity.
    J Med Virol. 2022 Nov 11. doi: 10.1002/jmv.28292.
    >> Share

  463. MOYO E, Moyo P, Mashe T, Dzobo M, et al
    Implementation of Public Health Genomics in Africa: Lessons from the COVID-19 pandemic, challenges, and recommendations.
    J Med Virol. 2022 Nov 11:e28295. doi: 10.1002/jmv.28295.
    >> Share

  464. HAN K, Wang J, Zou Y, Zhang Y, et al
    Association between emphysema and other pulmonary computed tomography patterns in COVID-19 pneumonia.
    J Med Virol. 2022 Nov 10:e28293. doi: 10.1002/jmv.28293.
    >> Share

  465. CHEE YJ, Fan BE, Young BE, Dalan R, et al
    Clinical trials on the pharmacological treatment of long COVID: a systematic review.
    J Med Virol. 2022 Nov 8. doi: 10.1002/jmv.28289.
    >> Share

  466. QIU S, Xu D, Dai J, Zhang L, et al
    Improving the efficiency and biosafety of respiratory syncytial virus identification using a nucleic acid extraction-free reagent.
    J Med Virol. 2022 Nov 7. doi: 10.1002/jmv.28287.
    >> Share

  467. BLANCO S, Aguilar JJ, Spinsanti L, Diaz A, et al
    Neutralization of B.1.617.2 variant through antibodies elicited by ChAdOx1-S, BBIBP-CorV and Gam-COVID-Vac in an Argentinean cohort.
    J Med Virol. 2022 Nov 7. doi: 10.1002/jmv.28286.
    >> Share


  468. Zhu, C, He, G, Yin, Q, et al. Molecular biology of the SARs-CoV-2 spike protein: A review of current knowledge. J Med Virol. 2021;93: 5729- 5741.
    J Med Virol. 2022 Nov 4. doi: 10.1002/jmv.28282.
    >> Share

  469. CAMACHO J, Gimenez E, Albert E, Zulaica J, et al
    Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant.
    J Med Virol. 2022 Nov 4:e28284. doi: 10.1002/jmv.28284.
    >> Share

  470. ZHAO L, Li Y, Yi W, Yan K, et al
    Reply to Chan, et al.
    J Med Virol. 2022 Nov 4. doi: 10.1002/jmv.28283.
    >> Share

  471. LIU C, Zhang J, Zeng Y, Huang C, et al
    Effectiveness of SARS-CoV-2 inactivated vaccine and the correlation to neutralizing antibodies: a test-negative case-control study.
    J Med Virol. 2022 Nov 3. doi: 10.1002/jmv.28280.
    >> Share

  472. LI X, Yin Y, Cui Q, Huang W, et al
    Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac inactivated booster: a 7-month follow-up study.
    J Med Virol. 2022 Nov 3. doi: 10.1002/jmv.28279.
    >> Share

  473. HE ST, Qin H, Guan L, Liu K, et al
    Bovine lactoferrin inhibits SARS-CoV-2 and SARS-CoV-1 by targeting the RdRp complex and alleviates viral infection in the hamster model.
    J Med Virol. 2022 Nov 3. doi: 10.1002/jmv.28281.
    >> Share

  474. FURUSE Y
    Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies.
    J Med Virol. 2022 Nov 3. doi: 10.1002/jmv.28275.
    >> Share

  475. SHMUELIAN Z, Warszawer Y, Or O, Arbel-Alon S, et al
    Post-exposure-vaccine-prophylaxis against COVID-19.
    J Med Virol. 2022 Nov 2. doi: 10.1002/jmv.28274.
    >> Share

  476. HALLMANN E, Sikora D, Poniedzialek B, Szymanski K, et al
    IgG autoantibodies against ACE2 in SARS-CoV-2 infected patients.
    J Med Virol. 2022 Nov 2. doi: 10.1002/jmv.28273.
    >> Share

  477. ROSENBAUER J, Stahl-Pehe A, Schlesinger S, Kuss O, et al
    Comments on Rahmati et al., The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic review and meta-analysis. J Med Virol. 2022; 1-16 (doi: 10.1002/jmv.27996).
    J Med Virol. 2022 Nov 2. doi: 10.1002/jmv.28272.
    >> Share

  478. LUCZKOWIAK J, Rivas G, Labiod N, Lasala F, et al
    Cross Neutralization of SARS-CoV-2 Omicron Subvariants after repeated doses of COVID-19 mRNA vaccines.
    J Med Virol. 2022 Nov 1. doi: 10.1002/jmv.28268.
    >> Share

  479. WEI Z, Jiang Y, Zhao G, Li C, et al
    Irradiation accelerates SARS-CoV-2 infection by enhancing sphingolipid metabolism.
    J Med Virol. 2022 Nov 1. doi: 10.1002/jmv.28266.
    >> Share

    October 2022
  480. BARANOVA A, Cao H, Teng S, Zhang F, et al
    A phenome-wide investigation of risk factors for severe COVID-19.
    J Med Virol. 2022 Oct 31. doi: 10.1002/jmv.28264.
    >> Share

  481. HUANG J, Fang Z, Huang L, Fan L, et al
    Effect of COVID-19 vaccination on semen parameters: a systematic review and meta-analysis.
    J Med Virol. 2022 Oct 30. doi: 10.1002/jmv.28263.
    >> Share


  482. Corrigendum.
    J Med Virol. 2022 Oct 29. doi: 10.1002/jmv.28261.
    >> Share

  483. ZHOU Y, Li GX, Zhao TS, Du J, et al
    Parents' willingness to vaccinate themselves and their children with the booster vaccine against SARS-CoV-2: a cross-sectional study in Puyang city, China.
    J Med Virol. 2022 Oct 28. doi: 10.1002/jmv.28256.
    >> Share

  484. ROUERS A, Wong N, Goh YS, Torres-Ruesta A, et al
    Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters.
    J Med Virol. 2022 Oct 27. doi: 10.1002/jmv.28258.
    >> Share

  485. MENG W, Guo S, Cao S, Shuda M, et al
    Development and Characterization of a New Monoclonal Antibody against SARS-CoV-2 NSP12.
    J Med Virol. 2022 Oct 21. doi: 10.1002/jmv.28246.
    >> Share

  486. GUO Z, Zhao S, Sun S, He D, et al
    Estimation of the serial interval of monkeypox during the early outbreak in 2022.
    J Med Virol. 2022 Oct 21. doi: 10.1002/jmv.28248.
    >> Share

  487. SHARMA D, Notarte KI, Fernandez RA, Lippi G, et al
    In silico evaluation of the impact of Omicron variant of concern sublineage BA.4 and BA.5 on the sensitivity of RT-qPCR assays for SARS-CoV-2 detection using whole genome sequencing.
    J Med Virol. 2022 Oct 19. doi: 10.1002/jmv.28241.
    >> Share

  488. ZHAO Y, Zhao Y, Zhang Y, Li M, et al
    Association of COVID-19 vaccination before conception with maternal thyroid function during early pregnancy: a single-center study in China.
    J Med Virol. 2022 Oct 19. doi: 10.1002/jmv.28245.
    >> Share

  489. BE S, Celikbilek A, Y K, B I, et al
    Neurological symptoms and neuronal damage markers in acute COVID 19: is there a correlation? A pilot study.
    J Med Virol. 2022 Oct 19. doi: 10.1002/jmv.28240.
    >> Share

  490. HE L, Zhong J, Li G, Lin Z, et al
    Development of SARS-CoV-2 animal vaccines using a stable and efficient NDV expression system.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28237.
    >> Share

  491. AL-EMRAN HM, Shaminur Rahman M, Hasan MS, Alam ASMRU, et al
    Microbiome analysis revealing microbial interactions and secondary bacterial infections in COVID-19 patients co-morbidly affected by type 2 diabetes.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28234.
    >> Share

  492. RAMIREZ-VELEZ R, Olabarrieta-Landa L, Rivera D, Izquierdo M, et al
    Factor Structure of the 10-item CES-D Scale Among Patients with Persistent COVID-19.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28236.
    >> Share

  493. GELENER P, Demirtas E
    Autoimmune seronegative limbic encephalitis following ChAdOx1-S/nCoV-19 vaccination in a patient with ankylosing spondylitis.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28235.
    >> Share

  494. ERDIK B
    Antiviral Treatment of COVID-19 is associated with lack of immune response.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28233.
    >> Share

  495. HORITA N, Fukumoto T
    Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic.
    J Med Virol. 2022 Oct 17. doi: 10.1002/jmv.28231.
    >> Share

  496. FISH CS, Owiti P, Begnel ER, Itell HL, et al
    Comparison of nucleocapsid and spike antibody ELISAs for determining SARS-CoV-2 seropositivity in Kenyan women and infants.
    J Med Virol. 2022 Oct 17. doi: 10.1002/jmv.28221.
    >> Share

  497. WU F, Yuan Y, Li Y, Yin D, et al
    The acceptance of SARS-CoV-2 rapid antigen self-testing: a cross-sectional study in China.
    J Med Virol. 2022 Oct 14. doi: 10.1002/jmv.28227.
    >> Share

  498. ZHOU L, Mo C, Yang Y, Zhou Z, et al
    Characterization and application of a series of monoclonal antibodies against SARS-CoV-2 nucleocapsid protein.
    J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28225.
    >> Share

  499. WANG M, Liu Z, Wang Z, Li K, et al
    Clinical characteristics of 1139 mild cases of the SARS-CoV-2 Omicron variant infected patients in Shanghai.
    J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28224.
    >> Share

  500. SHEN S, Rui Y, Wang Y, Su J, et al
    SARS-CoV-2, HIV, HPV: convergent evolution of selective regulation of cGAS-STING signaling.
    J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28220.
    >> Share

  501. LI L, Cui J, Tang J, Shi J, et al
    High titers of neutralizing antibodies in the blood fail to eliminate SARS-CoV-2 viral RNA in the upper respiratory tract.
    J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28219.
    >> Share

  502. PISAREVA E, Badiou S, Mihalovicova L, Mirandola A, et al
    Persistence of Neutrophil extracellular traps and anti-cardiolipin auto-antibodies in post-acute phase COVID-19 patients.
    J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28209.
    >> Share

  503. C AM, Singh AK, Roy P, Ravichandran M, et al
    Long COVID following Omicron wave in Eastern India - A retrospective cohort study.
    J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28214.
    >> Share

  504. NIRANJI SS, Amin Al-Jaf SM
    In response to: Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28213.
    >> Share

  505. LI X, Yuan H, Li X, Wang H, et al
    Spike protein mediated membrane fusion during SARS-CoV-2 infection.
    J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28212.
    >> Share

  506. GAHUKAR AM, Khairnar K
    Omicron variant of SARS-CoV-2: A pandemic of global concern warrants a cautious approach.
    J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28211.
    >> Share

  507. ZHANG Y, Ndzouboukou JB, Lin X, Hou H, et al
    SARS-CoV-2 evolves to reduce but not abolish neutralizing action.
    J Med Virol. 2022 Oct 11. doi: 10.1002/jmv.28207.
    >> Share

  508. MUKHERJEE AG, Wanjari UR, Kannampuzha S, Das S, et al
    The pathophysiological and immunological background of the monkeypox virus infection: An update.
    J Med Virol. 2022 Oct 11. doi: 10.1002/jmv.28206.
    >> Share

  509. YEUNG SLA, Wong THT, He B, Luo S, et al
    Does ACE2 mediate the detrimental effect of exposures related to COVID-19 risk: A Mendelian randomization investigation.
    J Med Virol. 2022 Oct 10. doi: 10.1002/jmv.28205.
    >> Share

  510. WANG P, Xu Y, Zhe SU, Xie C, et al
    Impact of COVID-19 Pandemic on Influenza virus Prevalence in Children in Sichuan, China.
    J Med Virol. 2022 Oct 10. doi: 10.1002/jmv.28204.
    >> Share

  511. RENGASAMY KR
    Will Monkeypox Outbreak mirror COVID-19 or AIDs?
    J Med Virol. 2022 Oct 10. doi: 10.1002/jmv.28202.
    >> Share

  512. CAMP JV, Redlberger-Fritz M
    Increased cases of Influenza C virus in children and adults in Austria, 2022.
    J Med Virol. 2022 Oct 9. doi: 10.1002/jmv.28201.
    >> Share

  513. MIGUERES M, Chapuy-Regaud S, Miedouge M, Jamme T, et al
    Current immunoassays and detection of antibodies elicited by Omicron SARS-CoV-2 infection.
    J Med Virol. 2022 Oct 7. doi: 10.1002/jmv.28200.
    >> Share

  514. BARANOVA A, Xu Y, Cao H, Zhang F, et al
    Associations between pulse rate and COVID-19.
    J Med Virol. 2022 Oct 6. doi: 10.1002/jmv.28194.
    >> Share

  515. MIRSHARIF ES, Chenary MR, Bozorgmehr M, Mohammadi S, et al
    Immunophenotyping Characteristics of COVID-19 Patients: Peripheral Blood CD8+ HLA-DR+ T Cells as a Biomarker for Mortality Outcome.
    J Med Virol. 2022 Oct 3. doi: 10.1002/jmv.28192.
    >> Share

  516. VALENTINA M, Alessandro CL, Francesca C, Silvia R, et al
    Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
    J Med Virol. 2022 Oct 2. doi: 10.1002/jmv.28186.
    >> Share

    September 2022
  517. GUNELL M, Rantasarkka K, Arjonen R, Sanden A, et al
    Clinical evaluation of an automated, rapid mariPOC(R) antigen test in screening of symptomatics and asymptomatics for SARS-CoV-2 infection.
    J Med Virol. 2022 Sep 30. doi: 10.1002/jmv.28189.
    >> Share

  518. XU W, Song D, Liu J, Han X, et al
    Development of chemiluminescent lab-on-fiber immunosensor for rapid point-of-care testing of anti-SARS-CoV-2 antibodies and evaluation of longitudinal immune response kinetics following three-dose inactivation virus vaccination.
    J Med Virol. 2022 Sep 30. doi: 10.1002/jmv.28190.
    >> Share

  519. YEO YH, Wang M, He X, Lv F, et al
    Excess risk for acute myocardial infarction mortality during the COVID-19 pandemic.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28187.
    >> Share

  520. SRIRAMAN K, Shaikh A, Vaswani S, Mestry T, et al
    Impact of COVID-19 vaccination on transmission risk of breakthrough infections: Lessons from Adapted N95 Mask Sampling for Emerging Variants and Interventions.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28188.
    >> Share

  521. NAGASAWA M, Kato T, Yamaguchi Y, Sugita Y, et al
    Rapid decrease of nasopharyngeal SARS-Co-V2 antigen in an outbreak of the Omicron strain.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28179.
    >> Share

  522. YANG J, Song H, Hao X
    Whole-transcriptome sequencing data reveals a disparate cognitive and immune signature in COVID-19 patients with and without dementia.
    J Med Virol. 2022 Sep 27. doi: 10.1002/jmv.28177.
    >> Share

  523. SU J, Shen S, Hu Y, Chen S, et al
    SARS-CoV-2 ORF3a inhibits cGAS-STING-mediated autophagy flux and antiviral function.
    J Med Virol. 2022 Sep 26. doi: 10.1002/jmv.28175.
    >> Share

  524. ZHOU J, Liu Z, Zhang G, Xu W, et al
    Development of variant-proof SARS-CoV-2, pan-sarbecovirus and pan-beta-coronavirus vaccines.
    J Med Virol. 2022 Sep 25. doi: 10.1002/jmv.28172.
    >> Share

  525. HANAFUSA M, Nawa N, Goto Y, Kawahara T, et al
    Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: a hospital-based observational study.
    J Med Virol. 2022 Sep 23. doi: 10.1002/jmv.28168.
    >> Share

  526. MESSALI S, Bugatti A, Filippini F, Caruso A, et al
    Emergence of S gene-based quasispecies explains an optimal adaptation of Omicron BA.5 subvariant in the immunocompetent vaccinated human host.
    J Med Virol. 2022 Sep 22. doi: 10.1002/jmv.28167.
    >> Share

  527. SILVA MFS, Pinto ACMD, Oliveira FCE, Caetano LF, et al
    Antibody response six months after the booster dose of Pfizer in previous recipients of CoronaVac.
    J Med Virol. 2022 Sep 22. doi: 10.1002/jmv.28169.
    >> Share

  528. FAVRESSE J, Gillot C, Bayart JL, David C, et al
    Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster.
    J Med Virol. 2022 Sep 21. doi: 10.1002/jmv.28164.
    >> Share

  529. DURAND GA, Amroun A, Grard G, Badaut C, et al
    Positive SARS-CoV-2 RT-qPCR of a nasal swab spot after 30 days of conservation on filter paper at room temperature.
    J Med Virol. 2022 Sep 21. doi: 10.1002/jmv.28165.
    >> Share

  530. VEGA-RODRIGUEZ W, Ly H
    GETTING AHEAD OF MONKEYPOX: Learning from the COVID-19 pandemic experience to prevent the potentially new monkeypox pandemic.
    J Med Virol. 2022 Sep 21. doi: 10.1002/jmv.28146.
    >> Share

  531. KONG W, Zhong Q, Chen M, Yu P, et al
    Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants.
    J Med Virol. 2022 Sep 20. doi: 10.1002/jmv.28163.
    >> Share

  532. KRISHNAMOORTHY S, Li GH, Cheung CL
    Transcriptome-wide Summary Data based Mendelian Randomization analysis reveals 38 novel genes associating with Severe COVID-19.
    J Med Virol. 2022 Sep 20. doi: 10.1002/jmv.28162.
    >> Share

  533. TAN Y, Lu S, Wang B, Duan X, et al
    Single-cell transcriptome atlas reveals protective characteristics of COVID-19 mRNA vaccine.
    J Med Virol. 2022 Sep 19. doi: 10.1002/jmv.28161.
    >> Share

  534. QIU X, Liu Y, Sha A
    SARS-CoV-2 and Natural Infection in Animals.
    J Med Virol. 2022 Sep 19. doi: 10.1002/jmv.28147.
    >> Share

  535. BOYTZ R, Slabicki M, Ramaswamy S, Patten JJ, et al
    Anti-SARS-CoV-2 Activity of Targeted Kinase Inhibitors: Repurposing Clinically Available Drugs for COVID-19 Therapy.
    J Med Virol. 2022 Sep 18. doi: 10.1002/jmv.28157.
    >> Share

  536. CECCARELLI G, d'Ettorre G, Russo A, Fabris S, et al
    SARS-CoV-2 pandemic, influenza, and influenza-like illness epidemics: Allies or enemies?
    J Med Virol. 2022 Sep 17. doi: 10.1002/jmv.28148.
    >> Share

  537. DESINGU PA, Nagarajan K
    Unveiling HERV-K113-ENV as SARS-CoV-2 severity admissible biomarker by mining transcriptome data.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28149.
    >> Share

  538. LI Z, Yong H, Wang W, Gao Y, et al
    GSK3326595 is a promising drug to prevent SARS-CoV-2 Omicron and other variants infection by inhibiting ACE2-R671 di-methylation.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28158.
    >> Share

  539. CENAT JM, Noorishad PG, Moshirian Farahi SMM, Darius WP, et al
    COVID-19 Vaccine Hesitancy and Related Factors in Canada: A Systematic Review and Meta-analysis.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28156.
    >> Share

  540. LI XK, Tu B, Zhang XA, Xu W, et al
    Dysregulation of glutamine/glutamate metabolism in COVID-19 patients: a metabolism study in African population and mini meta-analysis.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28150.
    >> Share

  541. KLOPFENSTEIN T, Gendrin V, Zayet S
    "Olfactory dysfunction in COVID-19, new insights from a cohort of 353 patients: The ANOSVID study": Author's reply.
    J Med Virol. 2022 Sep 15. doi: 10.1002/jmv.28151.
    >> Share

  542. LAN Q, Wang L, Jiao F, Lu L, et al
    Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.
    J Med Virol. 2022 Sep 13. doi: 10.1002/jmv.28143.
    >> Share

  543. CALABRETTO M, D'Alisa R, Faraone S, Mazzuti L, et al
    DETECTION OF SARS-COV-2 RNA AND ANTIBODIES IN BREAST MILK OF INFECTED MOTHERS.
    J Med Virol. 2022 Sep 13. doi: 10.1002/jmv.28142.
    >> Share

  544. FRYE CJ, Shine M, Makowski JA, Kensinger AH, et al
    Bioinformatics Analysis of the s2m Mutations within the SARS-CoV-2 Omicron Lineages.
    J Med Virol. 2022 Sep 13. doi: 10.1002/jmv.28141.
    >> Share

  545. ZHOU Y, Zhi H, Teng Y
    The outbreak of SARS-CoV-2 Omicron lineages, immune escape and vaccine effectivity.
    J Med Virol. 2022 Sep 12. doi: 10.1002/jmv.28138.
    >> Share

  546. LIANG LG, Zhu MJ, He R, Shi DR, et al
    Development of a multi-recombinase polymerase amplification assay for rapid identification of COVID-19, Influenza A and B.
    J Med Virol. 2022 Sep 11. doi: 10.1002/jmv.28139.
    >> Share

  547. QUEROMES G, Frobert E, Bouscambert-Duchamp M, Oblette A, et al
    Rapid and reliable inactivation protocols for the diagnostics of emerging viruses: the example of SARS-CoV-2 and monkeypox virus.
    J Med Virol. 2022 Sep 11. doi: 10.1002/jmv.28126.
    >> Share

  548. JIANG W, Johnson D, Adekunle R, Heather H, et al
    COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity.
    J Med Virol. 2022 Sep 10. doi: 10.1002/jmv.28134.
    >> Share

  549. LI Y, Yang J, Shen S, Wang W, et al
    SARS-CoV-2-encoded Inhibitors of Human LINE-1 Retrotransposition.
    J Med Virol. 2022 Sep 9. doi: 10.1002/jmv.28135.
    >> Share

  550. MARCHI L, Vidiri A, Fera EA, Pallottini M, et al
    SARS-CoV-2 IgG "heritage" in newborn: a credit of maternal natural infection.
    J Med Virol. 2022 Sep 7. doi: 10.1002/jmv.28133.
    >> Share

  551. CELIK E, Ozcan G, Vatansever C, Paerhati E, et al
    Alterations in Vaginal Microbiota among Pregnant Women with COVID-19.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28132.
    >> Share

  552. RZYMSKI P, Kasianchuk N, Sikora D, Poniedzialek B, et al
    COVID-19 Vaccinations and Rates of Infections, Hospitalizations, ICU Admissions, and Deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28131.
    >> Share

  553. FAIZO AA, Qashqari FS, El-Kafrawy SA, Barasheed O, et al
    A Potential Association between Obesity and Reduced Effectiveness of COVID-19 Vaccine-Induced Neutralizing Humoral Immunity.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28130.
    >> Share

  554. ABDALLA M, El-Arabey AA, Gai Z
    Hypertension is still a moving target in the context of COVID-19 and post-acute COVID-19 syndrome.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28128.
    >> Share

  555. AKASH S, Rahman MM, Islam MR, Sharma R, et al
    Emerging global concern of Langya Henipavirus: Pathogenicity, Virulence, Genomic features, and Future perspectives.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28127.
    >> Share

  556. SCARPA F, Sanna D, Azzena I, Giovanetti M, et al
    On the SARS-CoV-2 BA.2.75 variant: a genetic and structural point of view.
    J Med Virol. 2022 Sep 4. doi: 10.1002/jmv.28119.
    >> Share

  557. NICOT F, Tremeaux P, Latour J, Nicolas J, et al
    WHOLE GENOME SEQUENCING OF SARS-CoV-2: COMPARISON OF TARGET CAPTURE AND AMPLICON SINGLE MOLECULAR REAL TIME SEQUENCING PROTOCOLS.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28123.
    >> Share

  558. ARISH M, Qian W, Narasimhan H, Sun J, et al
    COVID-19 immunopathology: From acute diseases to chronic sequelae.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28122.
    >> Share

  559. WETTSTEIN L, Immenschuh P, Weil T, Conzelmann C, et al
    Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28124.
    >> Share

  560. YU T, Liu F, Yi N, Yin H, et al
    Evaluating agreement in different diagnosis methods is necessary.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28117.
    >> Share

  561. WANG C, Liu B, Zhang S, Huang N, et al
    Differences in incidence and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in relation to vaccine coverage: a world-wide review.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28118.
    >> Share

  562. WANG Q, Ye SB, Zhou ZJ, Li JY, et al
    Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28116.
    >> Share

    August 2022
  563. KAYA Y, Gulcu O, Aksakal E, Kalkan K, et al
    A Significant Predictor of In-Hospital and Long-term Mortality and Progression In COVID-19 Patients: The End-Stage Liver Disease (MELD) Score Model.
    J Med Virol. 2022 Aug 31. doi: 10.1002/jmv.28109.
    >> Share

  564. BARANOVA A, Cao H, Zhang F
    Causal Effect of COVID-19 on Alzheimer's Disease: A Mendelian Randomization Study.
    J Med Virol. 2022 Aug 30. doi: 10.1002/jmv.28107.
    >> Share

  565. GENG Y, Wang Y
    Stability and transmissibility of SARS-CoV-2 in the environment.
    J Med Virol. 2022 Aug 30. doi: 10.1002/jmv.28103.
    >> Share

  566. YAO Y, Song H, Zhang F, Liu J, et al
    Genetic predisposition to blood cell indices in relation to severe COVID-19.
    J Med Virol. 2022 Aug 29. doi: 10.1002/jmv.28104.
    >> Share

  567. COLSON P, Gautret P, Delerce J, Chaudet H, et al
    The emergence, spread and vanishing of a French SARS-CoV-2 variant exemplifies the fate of RNA virus epidemics and obeys the Mistigri rule.
    J Med Virol. 2022 Aug 28. doi: 10.1002/jmv.28102.
    >> Share

  568. LIU S, Cai J, Li Y, Ying L, et al
    Outbreak of acute respiratory disease caused by human adenovirus type 7 and Human Coronavirus-229E in Zhejiang Province, China.
    J Med Virol. 2022 Aug 28. doi: 10.1002/jmv.28101.
    >> Share

  569. XIE J, Klemsz MJ, Kacena MA, Sandusky G, et al
    Inhibition of MEK signaling prevents SARS-CoV2-induced lung damage and improves the survival of infected mice.
    J Med Virol. 2022 Aug 28. doi: 10.1002/jmv.28094.
    >> Share

  570. GHANG B, Kim S, Kim J
    Autoimmune rheumatic disease after SARS-CoV-2 vaccination.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28092.
    >> Share

  571. CAO H, Baranova A, Wei X, Wang C, et al
    Bidirectional causal associations between type 2 diabetes and COVID-19.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28100.
    >> Share

  572. SALIMIAN J, Ahmadi A, Amani J, Olad G, et al
    Safety and Immunogenicity of a Recombinant Receptor Binding Domain-Based Protein Subunit Vaccine (Noora Vaccine) Against COVID-19 in Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28097.
    >> Share

  573. ALI AM, Tofiq AM, Rostam HM, Ali KM, et al
    Disease Severity and Efficacy of Homologous Vaccination Among Patients Infected with SARS-CoV-2 Delta or Omicron VOCs, Compared to Unvaccinated using Main Biomarkers.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28098.
    >> Share

  574. LIU H, Chang S, Chen S, Du Y, et al
    Highly sensitive and rapid detection of SARS-CoV-2 via a portable CRISPR-Cas13a-based lateral flow assay.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28096.
    >> Share

  575. PATERSON C, Davis D, Roche M, Bissett B, et al
    What are the long-term holistic health consequences of COVID-19 among survivors? An umbrella systematic review.
    J Med Virol. 2022 Aug 24. doi: 10.1002/jmv.28086.
    >> Share

  576. MENG Y, Zeng F, Sun H, Li Y, et al
    Clinical characteristics and outcomes of patients with COVID-19 and psoriasis.
    J Med Virol. 2022 Aug 24. doi: 10.1002/jmv.28085.
    >> Share

  577. DING C, Ni S, Zhang X, Xie J, et al
    Evaluation of humoral immune responses induced by different SARS-CoV-2 spike trimers from wild-type and emerging variants with individual, sequential, and combinational delivered strategies.
    J Med Virol. 2022 Aug 19. doi: 10.1002/jmv.28081.
    >> Share

  578. DE MICHELENA P, Olea B, Torres I, Gonzalez-Candelas F, et al
    SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2.
    J Med Virol. 2022 Aug 19. doi: 10.1002/jmv.28079.
    >> Share

  579. MA Z, Mao Y, Wang Y, Duan Z, et al
    Suicidal ideation and attempted suicide among cancer patients during the COVID-19 pandemic.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28076.
    >> Share

  580. ALI MA, Zhang GF, Hu C, Yuan B, et al
    Ultra-Rapid and Ultra-Sensitive Detection of SARS-CoV-2 Antibodies in COVID-19 Patients via A 3D-Printed Nanomaterial-Based Biosensing Platform.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28075.
    >> Share

  581. LIU H, Li Q, Xiang Y, Li H, et al
    An Outbreak of Acute Respiratory Disease Caused by HAdV-55 in Beijing, China, 2020.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28074.
    >> Share

  582. CUI A, Xie Z, Xu J, Hu K, et al
    Comparative analysis of the clinical and epidemiological characteristics of human influenza virus vs. human respiratory syncytial virus vs. human metapneumovirus infection in nine provinces of China during 2009-2021.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28073.
    >> Share

  583. TAO SS, Wang XY, Yang XK, Liu YC, et al
    COVID-19 and inflammatory bowel disease crosstalk: from emerging association to clinical proposal.
    J Med Virol. 2022 Aug 16. doi: 10.1002/jmv.28067.
    >> Share

  584. MOHEBI L, Karami H, Mirsalehi N, Ardestani NH, et al
    A delayed resurgence of respiratory syncytial virus (RSV) during the COVID-19 pandemic: An unpredictable outbreak in a small proportion of children in the Southwest of Iran, April 2022.
    J Med Virol. 2022 Aug 12. doi: 10.1002/jmv.28065.
    >> Share

  585. YU W, Guo Y, Zhang S, Kong Y, et al
    Proportion of asymptomatic infection and non-severe disease caused by SARS-CoV-2 Omicron variant: a systematic review.
    J Med Virol. 2022 Aug 12. doi: 10.1002/jmv.28066.
    >> Share

  586. GEISEN UM, Rose R, Neumann F, Ciripoi M, et al
    The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFalpha blockade.
    J Med Virol. 2022 Aug 9. doi: 10.1002/jmv.28063.
    >> Share

  587. THAKUR N, Das S, Kumar S, Maurya VK, et al
    Tracing the origin of Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): A systematic review and narrative synthesis.
    J Med Virol. 2022 Aug 9. doi: 10.1002/jmv.28060.
    >> Share

  588. JIA M, Wang X, Gong W, Zhong J, et al
    Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort study.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28055.
    >> Share

  589. CHEUNG PH, Ye ZW, Lui WY, Ong CP, et al
    Production of single-cycle infectious SARS-CoV-2 through a trans-complemented replicon.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28057.
    >> Share

  590. INFANTINO M, Manfredi M, Alessio MG, Previtali G, et al
    CLINICAL UTILITY OF CIRCULATING CALPROTECTIN TO ASSIST PREDICTION AND MONITORING OF COVID-19 SEVERITY: AN ITALIAN STUDY.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28056.
    >> Share

  591. KUMBHAKAR R, Neradilek M, Barnabas RV, Stewart J, et al
    Using Time Weighted Average Change from Baseline of SARS-CoV-2 Viral Load to Assess Impact of Hydroxychloroquine (HCQ) as Post-exposure Prophylaxis and Early Treatment for COVID-19.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28054.
    >> Share

  592. WANG H, Guo S, Yang H
    Rapid quantitative monitoring of SARS-CoV-2 spike protein mediated syncytia formation using split NanoLuc.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28053.
    >> Share

  593. ELBAYIYEV S, Simsek GK, Ceran B, Akin MS, et al
    Could red cell distribution width be used for predicting cardiac injury in neonates with COVID-19?
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28050.
    >> Share

  594. ZOU L, Zhang H, Zheng Z, Jiang Y, et al
    Serosurvey in SARS-CoV-2 inactivated vaccine-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variants.
    J Med Virol. 2022 Aug 5. doi: 10.1002/jmv.28049.
    >> Share

  595. ZHANG H, Ding Q, Yuan J, Han F, et al
    Susceptibility to mice and potential evolutionary characteristics of porcine deltacoronavirus.
    J Med Virol. 2022 Aug 4. doi: 10.1002/jmv.28048.
    >> Share


  596. Corrigendum.
    J Med Virol. 2022 Aug 4. doi: 10.1002/jmv.28046.
    >> Share

  597. SUNTRONWONG N, Kanokudom S, Auphimai C, Assawakosri S, et al
    Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
    J Med Virol. 2022 Aug 4. doi: 10.1002/jmv.28044.
    >> Share


  598. Corrigendum.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28043.
    >> Share

  599. LIM CC, Leeu JJ, Mok IY, Tan HZ, et al
    Influenza Vaccine Awareness and Acceptance in Kidney Disease during the Corononavirus Disease 2019 pandemic.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28039.
    >> Share

  600. KOJIMA Y, Nakakubo S, Kamada K, Yamashita Y, et al
    Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28037.
    >> Share

  601. LIANG W, Wang S, Wang H, Li X, et al
    When 3D genome technology meets viral infection, including SARS-CoV-2.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28040.
    >> Share

    July 2022
  602. PENG P, Deng H, Li Z, Chen Y, et al
    Distinct immune responses in the early phase to natural SARS-CoV-2 infection or vaccination.
    J Med Virol. 2022 Jul 29. doi: 10.1002/jmv.28034.
    >> Share

  603. MURPHY H, Ly H
    What are the levels of risk of humans contracting SARS-CoV-2 from pets and vice versa?
    J Med Virol. 2022 Jul 29. doi: 10.1002/jmv.28035.
    >> Share

  604. ALEXIEV I, Giovanetti M, Cella E, Ivanov I, et al
    Initial Introduction and Spread of the SARS-CoV-2 AY.4.2.1 Delta Variant in Bulgaria, a Genomic Insight.
    J Med Virol. 2022 Jul 28. doi: 10.1002/jmv.28033.
    >> Share

  605. ZHANG GF, Meng W, Chen L, Ding L, et al
    Neutralizing Antibodies to SARS-CoV-2 Variants of Concern Including Delta and Omicron in Subjects Receiving mRNA-1273, BNT162b2 and Ad26.COV2.S Vaccines.
    J Med Virol. 2022 Jul 28. doi: 10.1002/jmv.28032.
    >> Share

  606. KOJIMA N, Desai V, Klausner JD
    Distributing Effective SARS-CoV-2 Medicines in a Timely Manner.
    J Med Virol. 2022 Jul 26. doi: 10.1002/jmv.28030.
    >> Share

  607. POURAKBARI B, Mirbeyk M, Mahmoudi S, Sadeghi RH, et al
    Evaluation of response to different COVID-19 vaccines in vaccinated healthcare workers in a single center in Iran.
    J Med Virol. 2022 Jul 26. doi: 10.1002/jmv.28029.
    >> Share

  608. JANG EJ, Choe YJ, Yun GW, Wang S, et al
    Reinfection with SARS-CoV-2 in general population, South Korea; nationwide retrospective cohort study.
    J Med Virol. 2022 Jul 25. doi: 10.1002/jmv.28026.
    >> Share

  609. DU Y, Li W, Guo Y, Li L, et al
    Epidemiology and genetic characterization of human metapneumovirus in pediatric patients from Hangzhou China.
    J Med Virol. 2022 Jul 24. doi: 10.1002/jmv.28024.
    >> Share

  610. LIU R, Lin X, Chen B, Hou Z, et al
    The mutation features and geographical distributions of the surface glycoprotein (S gene) in SARS-CoV-2 strains: a comparative analysis of the early and current strains.
    J Med Virol. 2022 Jul 24. doi: 10.1002/jmv.28023.
    >> Share

  611. PENG H, Zheng B, Yang S, Du J, et al
    A soluble DR5-Fc chimeric protein (sDR5-Fc) attenuates inflammatory responses induced by coronavirus MHV-A59 and SARS-CoV-2.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28021.
    >> Share

  612. WANG X, Zhao X, Cui Y, Qiao R, et al
    Neutralization of Distinct Omicron Sublineages by Longitudinal Vaccination Sera.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28017.
    >> Share

  613. OSTERDAHL MF, Christakou E, Hart D, Harris F, et al
    Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19.
    J Med Virol. 2022 Jul 21. doi: 10.1002/jmv.28016.
    >> Share

  614. LIANG Y, Gong Z, Guo J, Cheng Q, et al
    Spatiotemporal analysis of the morbidity of global Omicron from November 2021 to February 2022.
    J Med Virol. 2022 Jul 21. doi: 10.1002/jmv.28013.
    >> Share

  615. WANG Y, Wang X, Luu LDW, Li J, et al
    Single-cell transcriptomic atlas reveals distinct immunological responses between COVID-19 vaccine and natural SARS-CoV-2 infection.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28012.
    >> Share

  616. YANG Y, Zhao R, Wang Y, Song D, et al
    Rapid and universal detection of SARS-CoV-2 and influenza A virus using a reusable dual-channel optic fiber immunosensor.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28015.
    >> Share

  617. CHEEMA HA, Shahid A, Aziz H
    Severe acute pediatric hepatitis: the undue emphasis on adenovirus needs to be reassessed.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28014.
    >> Share

  618. DE VITO A, Colpani A, Bitti A, Zauli B, et al
    Safety and efficacy of molnupiravir in SARS-CoV-2 infected patients: a real-life experience.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28011.
    >> Share

  619. HUANG D, Lin S, He J, Wang Q, et al
    Association between COVID-19 and telomere length: a bidirectional Mendelian randomization study.
    J Med Virol. 2022 Jul 19. doi: 10.1002/jmv.28008.
    >> Share

  620. MONARI C, Pisaturo M, Maggi P, Macera M, et al
    EARLY PREDICTORS OF CLINICAL DETERIORATION IN A COHORT OF OUTPATIENTS WITH COVID-19 IN SOUTHERN ITALY: A MULTICENTER OBSERVATIONAL STUDY.
    J Med Virol. 2022 Jul 19. doi: 10.1002/jmv.28007.
    >> Share

  621. HUANG N, Wang C, Han B, Zhao T, et al
    Change in willingness to COVID-19 vaccination in China: two online surveys during the pandemic.
    J Med Virol. 2022 Jul 18. doi: 10.1002/jmv.28004.
    >> Share

  622. BAUER G, Struck F, Staschik E, Maile J, et al
    Differential avidity determination of IgG directed towards the receptor-binding domain (RBD) of SARS-CoV-2 wild-type and its variants in one assay: Rational tool for the assessment of protective immunity.
    J Med Virol. 2022 Jul 18. doi: 10.1002/jmv.28006.
    >> Share

  623. CHEN J, Liu X, Liu W, Yang C, et al
    Comparison of the respiratory tract microbiome in hospitalized COVID-19 patients with different disease severity.
    J Med Virol. 2022 Jul 15. doi: 10.1002/jmv.28002.
    >> Share

  624. JASIM SA, Mahdi RS, Bokov DO, Najm MAA, et al
    The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update.
    J Med Virol. 2022 Jul 14. doi: 10.1002/jmv.28000.
    >> Share

  625. VAIRA LA, De Riu G, Boscolo-Rizzo P, Hopkins C, et al
    In response to: Olfactory dysfunction in COVID-19, new insights from a cohort of 353 patients: The ANOSVID study.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27999.
    >> Share

  626. FERRAVANTE C, Arslan-Gatz BS, Dell'Annunziata F, Palumbo D, et al
    Dynamics of nasopharyngeal tract phageome and association with disease severity and age of patients during three waves of COVID-19.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27998.
    >> Share

  627. FILHO FFD, Chaves EBM, D'Avila KG, Neyeloff JL, et al
    Clinical characteristics and outcomes of healthcare workers with COVID-19 pre- and postvaccination.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27997.
    >> Share

  628. RAHMATI M, Keshvari M, Mirnasuri S, Yon DK, et al
    The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic review and meta-analysis.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27996.
    >> Share

  629. CHEN J, Song J, Dai L, Post SR, et al
    SARS-CoV-2 Infection and Lytic Reactivation of Herpesviruses: a Potential Threat at Post-pandemic Era?
    J Med Virol. 2022 Jul 12. doi: 10.1002/jmv.27994.
    >> Share

  630. FARHEEN S, Araf Y, Tang YD, Zheng C, et al
    The Deltacron conundrum: its origin and potential health risks.
    J Med Virol. 2022 Jul 11. doi: 10.1002/jmv.27990.
    >> Share

  631. RANKIN DA, Yanis A, Talj R, Howe HL, et al
    Clinical Presentations of Adult and Pediatric SARS-CoV-2-Positive Cases in a Community Cohort, Nashville, Tennessee.
    J Med Virol. 2022 Jul 11. doi: 10.1002/jmv.27988.
    >> Share

  632. DUMAN N, Tuncel G, Bisgin A, Bozdogan ST, et al
    "Analysis of ACE2 and TMPRSS2 coding variants as a risk factor for SARS-CoV-2 from 946 whole exome sequencing data in the Turkish Population.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27976.
    >> Share

  633. ALMUFTY HB, Mamani MMA, Ali AH, Merza MA, et al
    COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan; a retrospective cohort study.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27985.
    >> Share

  634. TEO KW, Patel D, Sisodia S, Roland D, et al
    Rhinovirus persistence during the COVID-19 pandemic - impact on paediatric acute wheezing admissions.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27986.
    >> Share

  635. QI X, Wang J, Zhang Q, Ai J, et al
    Safety and Immunogenicity of COVID-19 Vaccination in Patients with Hepatocellular Carcinoma (CHESS-NMCID 2101): A Multicenter Prospective Study.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27992.
    >> Share

  636. CARDENOSO DOMINGO L, Roy Vallejo E, Zurita Cruz ND, Chicot Llano M, et al
    Relevant SARS-CoV-2 viremia is associated with COVID-19 severity: prospective cohort study and validation cohort.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27989.
    >> Share

  637. CHENG ZJ, Huang H, Liu Q, Zhong R, et al
    Immunoassay and mass cytometry revealed immunological profiles induced by inactivated BBIBP COVID-19 vaccine.
    J Med Virol. 2022 Jul 8. doi: 10.1002/jmv.27983.
    >> Share

  638. PETRIE JG, Eisenberg MC, Lauring AS, Gilbert J, et al
    Variant-specific burden of SARS-CoV-2 in Michigan: March 2020 through November 2021.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27982.
    >> Share

  639. CHIRUMBOLO S
    Myopericarditis in young subjects after vaccination, clearing the clouds of misunderstanding.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27981.
    >> Share

  640. ZENG G, Wang X
    Ending the COVID-19 pandemic: We still have a long way to go.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27980.
    >> Share

  641. VELAZQUEZ-SALINAS L
    The complex evolutionary dynamics of SARS-CoV-2, a big challenge to control the pandemic of COVID-19.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27979.
    >> Share

  642. YUASA S, Nakajima J, Takatsuki Y, Takahashi Y, et al
    Viral load of SARS-CoV-2 Omicron is not high despite its high infectivity.
    J Med Virol. 2022 Jul 5. doi: 10.1002/jmv.27974.
    >> Share

  643. AKSAK T, Satar DA, Ridvan B, Gultekin EO, et al
    INVESTIGATION OF THE EFFECT OF COVID-19 ON SPERM COUNT, MOTILITY AND MORPHOLOGY.
    J Med Virol. 2022 Jul 1. doi: 10.1002/jmv.27971.
    >> Share

    June 2022
  644. DESINGU PA, Nagarajan K
    The emergence of Omicron lineages BA.4 and BA.5, and the global spreading trend.
    J Med Virol. 2022 Jun 30. doi: 10.1002/jmv.27967.
    >> Share

  645. HAN L, Zheng Y, Deng J, Nan ML, et al
    SARS-CoV-2 ORF10 antagonizes STING-dependent interferon activation and autophagy.
    J Med Virol. 2022 Jun 28. doi: 10.1002/jmv.27965.
    >> Share

  646. CRUZ CA, Medina PM
    Temporal Changes in the Accessory Protein Mutations of SARS-CoV-2 Variants and Their Predicted Structural and Functional Effects.
    J Med Virol. 2022 Jun 28. doi: 10.1002/jmv.27964.
    >> Share

  647. AKCAY N, Bektas G, Menentoglu ME, Sevketoglu E, et al
    Response to Finsterer on the letter to the editor ''Diagnose SARS-CoV-2 associated Guillain-Barre syndrome upon appropriate criteria and after exclusion of differentials''.
    J Med Virol. 2022 Jun 27. doi: 10.1002/jmv.27960.
    >> Share

  648. TAVAKOLI N, Nafissi N, Shokri S, Fallahpour M, et al
    Pediatric and Adolescent COVID-19 Vaccination Side Effects: A Retrospective Cohort Study of Iranian Teenage group in 2021.
    J Med Virol. 2022 Jun 27. doi: 10.1002/jmv.27962.
    >> Share

  649. CIMOLAI N
    Disinfection and Decontamination in the Context of SARS-CoV-2 Specific Data.
    J Med Virol. 2022 Jun 27. doi: 10.1002/jmv.27959.
    >> Share

  650. LI D, Xiong L, Pan G, Wang T, et al
    Molecular Imaging on ACE2-dependent Transocular Infection of Coronavirus.
    J Med Virol. 2022 Jun 26. doi: 10.1002/jmv.27958.
    >> Share

  651. UMAIR M, Ikram A, Rehman Z, Haider SA, et al
    Genomic diversity of SARS-CoV-2 in Pakistan during the fourth wave of pandemic.
    J Med Virol. 2022 Jun 26. doi: 10.1002/jmv.27957.
    >> Share

  652. TANG K, Wei Z, Wu X
    Impaired serological response to COVID-19 vaccination following anti-cancer therapy: a systematic review and meta-analysis.
    J Med Virol. 2022 Jun 24. doi: 10.1002/jmv.27956.
    >> Share

  653. KONTOPOULOU K, Nakas CT, Belai C, Papazisis G, et al
    Antibody Titers After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in immunocompromised adults in Greece: is a fourth dose necessary?
    J Med Virol. 2022 Jun 23. doi: 10.1002/jmv.27954.
    >> Share

  654. MIAO G, Peng H, Tang H, Liu Y, et al
    Antiviral efficacy of selective estrogen receptor modulators against SARS-CoV-2 infection in vitro and in vivo reveals bazedoxifene acetate as an entry inhibitor.
    J Med Virol. 2022 Jun 22. doi: 10.1002/jmv.27951.
    >> Share

  655. TASEEN S, Nasir F, Abbas M, Altaf M, et al
    Post-pandemic World at the Mercy of Monkeypox Virus Outbreak: Time to worry or not?
    J Med Virol. 2022 Jun 22. doi: 10.1002/jmv.27948.
    >> Share

  656. CHEN JM, Li GH, Ji YF, Sun MH, et al
    A highly powerful non-specific strategy to reduce COVID-19 deaths.
    J Med Virol. 2022 Jun 21. doi: 10.1002/jmv.27949.
    >> Share

  657. PHAN T, Boes S, McCullough M, Gribschaw J, et al
    Emergence of SARS-CoV-2 Omicron BA.5 variant of concern in Western Pennsylvania, United States.
    J Med Virol. 2022 Jun 17. doi: 10.1002/jmv.27945.
    >> Share

  658. STAERK-OSTERGAARD J, Kirkeby C, Christiansen LE, Andersen MA, et al
    Evaluation of diagnostic test procedures for SARS-CoV-2 using latent class models.
    J Med Virol. 2022 Jun 17. doi: 10.1002/jmv.27943.
    >> Share

  659. WOLF JM, Petek H, Maccari JG, Nasi LA, et al
    COVID-19 pandemic in Southern Brazil: Hospitalizations, intensive care unit admissions, lethality rates, and length of stay between March 2020 and April 2022.
    J Med Virol. 2022 Jun 16. doi: 10.1002/jmv.27942.
    >> Share

  660. CEYLAN MR, Kankilic N, Oz O
    Are H1 and H3 haplotypes of endothelial protein C receptor (PROCR) an important factor in contracting COVID-19?
    J Med Virol. 2022 Jun 16. doi: 10.1002/jmv.27938.
    >> Share

  661. TIAN F, Yang R
    Safety and Efficacy of COVID-19 Vaccines in Children and Adolescents: a Systematic Review of Randomized Controlled Trials.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27940.
    >> Share

  662. WANG L, Zhou HY, Li JY, Cheng YX, et al
    Potential Inter-variant and Intra-variant Recombination of Delta and Omicron Variants.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27939.
    >> Share

  663. WELLS DA, Cantoni D, Mayora-Neto M, Di Genova C, et al
    Human seasonal coronavirus neutralisation and COVID-19 severity.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27937.
    >> Share

  664. AKASH K, Sharma A, Kumar D, Singh SK, et al
    MOLECULAR ASPECTS OF OMICRON, VACCINE DEVELOPMENT AND RECOMBINANT STRAIN XE: A REVIEW.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27936.
    >> Share

  665. LYTRAS T, Kontopidou F, Lambrou A, Tsiodras S, et al
    Comparative effectiveness and durability of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign.
    J Med Virol. 2022 Jun 14. doi: 10.1002/jmv.27934.
    >> Share

  666. ATLURI VL, Stalter RM, McGuffin SA, Johnson L, et al
    Patient Characteristics Associated with Conversion from Negative to Positive SARS-CoV2 PCR Test Results: Implications for Clinical False-Negativity from a Single-Center: A Case-Control Study.
    J Med Virol. 2022 Jun 14. doi: 10.1002/jmv.27932.
    >> Share

  667. RUDIANSYAH M, Jasim SA, Mohammad Pour ZG, Athar SS, et al
    Coronavirus disease 2019 (COVID-19) update: From metabolic reprogramming to immunometabolism.
    J Med Virol. 2022 Jun 10. doi: 10.1002/jmv.27929.
    >> Share

  668. KUMAR S, Karuppanan K, Subramaniam G
    Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
    J Med Virol. 2022 Jun 9. doi: 10.1002/jmv.27927.
    >> Share

  669. GIRAY BG, Acik GG
    SARS-CoV-2and Mutation RT-qPCR Test Positivity Correlation with ABO and Rh Blood Types.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27923.
    >> Share

  670. CHEN YQ, Ji YF, Chen JM
    Dual impacts of the COVID-19 non-pharmaceutical interventions on other infectious diseases.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27922.
    >> Share

  671. LI H, Chen Z, Liu X, Hu P, et al
    T cell epitopes are largely conserved in the SARS-CoV-2 Omicron subvariant (BA.1, BA.2, BA.3 and GKA).
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27925.
    >> Share

  672. CHEUNG CL, Ho SC, Krishnamoorthy S, Li GH, et al
    COVID-19 and Platelet Traits: A Bi-directional Mendelian Randomization Study.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27920.
    >> Share

  673. MERCIER J, Osman M, Bouiller K, Tipirdamaz C, et al
    Olfactory dysfunction in COVID-19, new insights from a cohort of 353 patients: the ANOSVID study.
    J Med Virol. 2022 Jun 7. doi: 10.1002/jmv.27918.
    >> Share

  674. IDIZ UO, Yurttas TT, Degirmencioglu S, Orhan B, et al
    Immunophenotyping of lymphocytes and monocytes and the status of cytokines in the clinical course of Covid-19 patients.
    J Med Virol. 2022 Jun 6. doi: 10.1002/jmv.27917.
    >> Share

  675. TSAGKARIS C, Eleftheriades A, Laubscher L, Vladyckuk V, et al
    Viruses monkeying around with surgical safety: Monkeypox preparedness in surgical settings.
    J Med Virol. 2022 Jun 3. doi: 10.1002/jmv.27915.
    >> Share

  676. BREHM TT, Pfefferle S, von Possel R, Karolyi M, et al
    Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for SARS-CoV-2 delta and omicron variants.
    J Med Virol. 2022 Jun 3. doi: 10.1002/jmv.27916.
    >> Share

  677. ZHAO L, Li Y, Yi W, Yan K, et al
    The clinical and bioinformatics analysis for the role of anti-hypertension drugs on mortality among patients with hypertension hospitalized with COVID-19.
    J Med Virol. 2022 Jun 3. doi: 10.1002/jmv.27914.
    >> Share

  678. AU TY, Assavarittirong C
    The potential rationale of COVID-19 vaccine-induced myopericarditis.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27910.
    >> Share

  679. SAIED AA, Nascimento MSL, Rangel AHDN, Skowron K, et al
    Transchromosomic bovines (TcB)-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1 and Influenza A virus.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27907.
    >> Share

  680. MAK GCK, Lau SSY, Wong KKY, Lau CS, et al
    Analytical sensitivity of the Rapid Antigen Test kits for detection of SARS-CoV-2 Omicron variant BA.2 sublineage.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27908.
    >> Share

  681. NAH EH, Cho S, Park H, Kim S, et al
    Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: a prospective observational study.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27911.
    >> Share

  682. OKTAY GULTEKIN E, Gultekin O, Coskun A, Aksak T, et al
    Antibody response three months after SARS-CoV-2 infection.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27909.
    >> Share

  683. URSIC T, Kogoj R, Sikonja J, Roskaric D, et al
    Performance of nasopharyngeal swab and saliva in detecting Delta and Omicron SARS-CoV-2 variants.
    J Med Virol. 2022 Jun 1. doi: 10.1002/jmv.27898.
    >> Share

    May 2022
  684. LIU P, Xu M, Lu L, Ma A, et al
    The changing pattern of common respiratory and enteric viruses among outpatient children in Shanghai, China: Two years of the COVID-19 pandemic.
    J Med Virol. 2022 May 31. doi: 10.1002/jmv.27896.
    >> Share

  685. KOZAWA K, Miura H, Kawamura Y, Higashimoto Y, et al
    Unremarkable antibody responses against various infectious agents after inoculation with the BNT162b2 COVID-19 vaccine.
    J Med Virol. 2022 May 31. doi: 10.1002/jmv.27895.
    >> Share

  686. MESTANZA O, Lizarraga W, Padilla-Rojas C, Jimenez-Vasquez V, et al
    GENOMIC SURVEILLANCE OF LAMBDA SARS-COV-2 VARIANT IN A GLOBAL PHYLOGENETIC CONTEXT.
    J Med Virol. 2022 May 29. doi: 10.1002/jmv.27889.
    >> Share

  687. KHORATTANAKULCHAI N, Manopwisedjaroen S, Rattanapisit K, Panapitakkul C, et al
    Receptor Binding Domain Proteins of SARS-CoV-2 Variants Produced in Nicotiana benthamiana Elicit Neutralizing Antibodies Against Variants of Concern.
    J Med Virol. 2022 May 26. doi: 10.1002/jmv.27881.
    >> Share

  688. FLEISCHER B, Olum R, Nakwagala FN, Nassozi DR, et al
    Higher intensive care unit consultations for COVID-19 patients living with HIV compared to those without HIV coinfection in Uganda.
    J Med Virol. 2022 May 26. doi: 10.1002/jmv.27887.
    >> Share

  689. GAO X, Hao J, Yu L, Cao Y, et al
    Evaluation of enterovirus nucleic acids detection method based on ultra-fast real-time fluorescence RT-PCR technology - A pilot study.
    J Med Virol. 2022 May 26. doi: 10.1002/jmv.27886.
    >> Share

  690. NGUYEN-KIM H, Beckmann C, Redondo M, Ziliox J, et al
    COVID Salivary diagnostics: a comparative technical study.
    J Med Virol. 2022 May 25. doi: 10.1002/jmv.27883.
    >> Share

  691. DU P, Li N, Xiong X, Tang S, et al
    A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    J Med Virol. 2022 May 25. doi: 10.1002/jmv.27885.
    >> Share

  692. JIANG Y, Zhang H, Yu J, Huang D, et al
    Humoral immune response to authentic circulating SARS-CoV-2 variants elicited by booster vaccination with distinct RBD subunits in mice.
    J Med Virol. 2022 May 25. doi: 10.1002/jmv.27882.
    >> Share

  693. SIVAN M, Preston N, Parkin A, Makower S, et al
    The modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) patient-reported outcome measure for Long Covid or Post-COVID-19 syndrome.
    J Med Virol. 2022 May 23. doi: 10.1002/jmv.27878.
    >> Share

  694. LIU S, Li W, Jiang S
    Disease of influenza virus and SARS-CoV-2 coinfection: Flurona or Flucovid?
    J Med Virol. 2022 May 19. doi: 10.1002/jmv.27874.
    >> Share

  695. LEE CJ, Woo W, Kim AY, Yon DK, et al
    Clinical Manifestations of COVID-19 Breakthrough Infections: A Systematic Review and Meta-Analysis.
    J Med Virol. 2022 May 19. doi: 10.1002/jmv.27871.
    >> Share

  696. TORRES I, Gimenez E, Albert E, Zulaica J, et al
    SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty(R) COVID-19 vaccine: Looking for correlates of protection.
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27867.
    >> Share

  697. VILLACRES B, Paz E, Burbano MJ, Villacres-Granda I, et al
    Neutralizing activity to SARS-CoV-2 in 1.2 to 10.0 month convalescent plasma samples of COVID-19: a transversal surrogate in vitro study performed in Quito-Ecuador.
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27866.
    >> Share

  698. CAI S, Liao G, Yu T, Gao Q, et al
    Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study.
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27872.
    >> Share

  699. CHIRUMBOLO S
    May the concurrent use of indomethacin and an anti-oxidant in the SARS-CoV2 infection treatment induce an exacerbation of COVID-19?
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27868.
    >> Share

  700. YE Y, Ye Z, Yang L, Xiang B, et al
    Unignorable public health risk of avian influenza virus during COVID-19 pandemic.
    J Med Virol. 2022 May 17. doi: 10.1002/jmv.27864.
    >> Share

  701. NILGIRIWALA K, Kadam P, Patel G, Shaikh A, et al
    Genomics of Post-Vaccination SARS-CoV-2 Infections During the Delta Dominated Second Wave of COVID-19 Pandemic, from Mumbai Metropolitan Region (MMR), India.
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27861.
    >> Share

  702. KUITUNEN I, Artama M, Haapanen M, Renko M, et al
    Respiratory virus circulation in children after relaxation of COVID-19 restrictions in fall 2021 - a nationwide register study in Finland.
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27857.
    >> Share

  703. BEAUDOIN CA, Pandurangan AP, Kim SY, Hamaia SW, et al
    In silico analysis of mutations near S1/S2 cleavage site in SARS-CoV-2 spike protein reveals increased propensity of glycosylation in Omicron strain.
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27845.
    >> Share

  704. YU T, Ling Q, Xu M, Wang N, et al
    ORF8 protein of SARS-CoV-2 reduces male fertility in mice.
    J Med Virol. 2022 May 15. doi: 10.1002/jmv.27855.
    >> Share

  705. CHO K, Park S, Kim EY, Koyanagi A, et al
    Immunogenicity of COVID-19 Vaccines in Patients with Diverse Health Conditions: a Comprehensive Systematic Review.
    J Med Virol. 2022 May 13. doi: 10.1002/jmv.27828.
    >> Share

  706. VAKIL MK, Mansoori Y, Al-Awsi GRL, Hosseinipour A, et al
    Individual Genetic Variability Mainly of Proinflammatory Cytokines, Cytokine Receptors and Toll-like receptors Dictates Pathophysiology of COVID-19 Disease.
    J Med Virol. 2022 May 10. doi: 10.1002/jmv.27849.
    >> Share

  707. CLEMENTINO M, Cavalcante KF, Viana VAF, Silva DO, et al
    Detection of SARS-CoV-2 in Different Human Biofluids Using the Loop-Mediated Isothermal Amplification Assay: A Prospective Diagnostic Study in Fortaleza, Brazil.
    J Med Virol. 2022 May 10. doi: 10.1002/jmv.27842.
    >> Share

  708. LEVESQUE S, Beauchemin S, Vallee M, Longtin J, et al
    Evaluation of water gargle samples for SARS-CoV-2 detection using Abbott ID NOW COVID-19 assay.
    J Med Virol. 2022 May 9. doi: 10.1002/jmv.27847.
    >> Share

  709. PHAN T, Boes S, McCullough M, Gribschaw J, et al
    First detection of SARS-CoV-2 Omicron BA.4 variant in Western Pennsylvania, United States.
    J Med Virol. 2022 May 9. doi: 10.1002/jmv.27846.
    >> Share

  710. ZERBINATI RM, Palmieri M, Schwab G, Felix AC, et al
    Use of Saliva and RT-PCR Screening for SARS-CoV-2 Variants of Concern: Surveillance and Monitoring.
    J Med Virol. 2022 May 6. doi: 10.1002/jmv.27839.
    >> Share

  711. WENG Y, Yi GY
    Estimation of the COVID-19 Mean Incubation Time: Systematic Review, Meta-analysis, and Sensitivity Analysis.
    J Med Virol. 2022 May 6. doi: 10.1002/jmv.27841.
    >> Share

  712. LIN Z, Cheng M, Zhu F, Yang X, et al
    Immunogenicity and safety of different platforms of COVID-19 vaccines given as a 3rd (booster) dose in healthy adults.
    J Med Virol. 2022 May 6. doi: 10.1002/jmv.27836.
    >> Share

  713. DAI Y, Zhong J, Lan Y
    Virus-virus interactions of febrile respiratory syndrome among patients in China based on surveillance data from February 2011 to December 2020.
    J Med Virol. 2022 May 5. doi: 10.1002/jmv.27833.
    >> Share

  714. SIMSEK M, Yasin AI, Besiroglu M, Topcu A, et al
    The Efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac Vaccines in Patients with Cancer.
    J Med Virol. 2022 May 5. doi: 10.1002/jmv.27835.
    >> Share

  715. KIM KW, Wang X, Adhikari A, Yeang M, et al
    Persistent high-level shedding of cultivable SARS-CoV-2 Delta virus 33 days after onset of COVID-19 in a hospitalized patient with pneumonia.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27832.
    >> Share

  716. KEIJSERS CJPW, Broeders MEAC, Baptista Lopes V, Klinkert AF, et al
    Memory impairment and concentration problems in COVID-19 survivors eight weeks after non-ICU hospitalization: a retrospective cohort study.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27831.
    >> Share

  717. ISLAM F, Dhawan M, Mitra S, Bin Emran T, et al
    Assessing the risks associated with the emergence of Florona and possible preventive measures.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27830.
    >> Share

  718. PEIXOTO SG, Wolf JM, Glaeser AB, Maccari JG, et al
    Longer length of stay, days between discharge/first readmission, and pulmonary involvement >/=50% increase prevalence of admissions in ICU in unplanned readmissions after COVID-19 hospitalizations.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27792.
    >> Share

  719. WU F, Yuan Y, Deng Z, Yin D, et al
    Acceptance of COVID-19 Booster Vaccination Based on the Protection Motivation Theory (PMT): A Cross-Sectional Study in China.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27825.
    >> Share

  720. FONSECA MHG, Silva MFS, Pinto ACMD, Melo ACL, et al
    Persistently positive SARS-CoV-2 specific IgM during one-year follow-up.
    J Med Virol. 2022 May 3. doi: 10.1002/jmv.27822.
    >> Share

  721. SHAFIEE A, Aghajanian S, Athar MMT, Gargari OK, et al
    Epstein-Barr virus and COVID-19.
    J Med Virol. 2022 May 3. doi: 10.1002/jmv.27823.
    >> Share

  722. KHOKHER W, Beran A, Iftikhar S, Malhas SE, et al
    Pulse versus Non-pulse Steroid Regimens in Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.
    J Med Virol. 2022 May 3. doi: 10.1002/jmv.27824.
    >> Share

  723. SEDIGHI M, Amanollahi A, Moghaddam OM, Ghafouri HB, et al
    Linear mixed model analysis to evaluate correlations between remdesivir adverse effects with age and gender of patients with mild Covid-19 pneumonia.
    J Med Virol. 2022 May 2. doi: 10.1002/jmv.27800.
    >> Share

  724. MAJUMDAR S, Sarkar R
    Mutational and phylogenetic analyses of the two lineages of the Omicron variant.
    J Med Virol. 2022;94:1777-1779.
    >> Share

    April 2022
  725. BANERJEE S, Wang X, Du S, Zhu C, et al
    Comprehensive Role of SARS-CoV-2 Spike Glycoprotein in Regulating Host Signaling Pathway.
    J Med Virol. 2022 Apr 29. doi: 10.1002/jmv.27820.
    >> Share

  726. KHAN YH, Mallhi TH, Alanazi AS, Butt MH, et al
    Outbreak of Acute Hepatitis of Unknown etiology in Children; The Critical Role of Healthcare Professionals in Neutralizing Misleading Narratives during the COVID-19 Pandemic.
    J Med Virol. 2022 Apr 29. doi: 10.1002/jmv.27819.
    >> Share

  727. TASAR S, Karadag-Oncel E, Yilmaz-Ciftdogan D, Kara-Aksay A, et al
    Influenza is More Severe than Our Newest Enemy (COVID-19) in Hospitalized Children: Experience from a Tertiary Center.
    J Med Virol. 2022 Apr 27. doi: 10.1002/jmv.27817.
    >> Share

  728. QAMAR N, Rukh G, Khan SN
    Vaccines for Covid-19: An Insight on Their Effectiveness and Adverse Effects.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27810.
    >> Share

  729. LI Y, Wang X, Jin J, Ma Z, et al
    T cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27814.
    >> Share

  730. SUN ZP, Yang SY, Cai X, Han WD, et al
    Survival of SARS-CoV-2 in artificial seawater and on the surface of inanimate materials.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27807.
    >> Share

  731. GUPTA N, Wilson W, Ravindra P, Raghu R, et al
    Coinfection of leptospirosis and Coronavirus disease 2019: a retrospective case series from a coastal region in South India.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27816.
    >> Share

  732. PRAZUCK T, Gravier A, Pires-Roteira D, Theillay A, et al
    Evaluation of A NEW "All in One" SARS-CoV-2 antigen-detecting rapid diagnostic test AND self-test: diagnostic performance and usability in child and adult populationS.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27812.
    >> Share

  733. ZHOU B, Song S, Guo H, Zhou X, et al
    A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27811.
    >> Share

  734. RAMIREZ AL, Luna N, Patino LH, Castaneda S, et al
    Impact of SARS-CoV-2 Mu variant on vaccine effectiveness: a comparative genomics study at the peak of the third wave in Bogota, Colombia.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27808.
    >> Share

  735. ZHANG J, Cao J, Ye Q
    Nonpharmaceutical interventions against the COVID-19 pandemic significantly decreased the spread of enterovirus in children.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27806.
    >> Share

  736. JAIN S, Meena R, Kumar V, Kaur R, et al
    Comparison of haematologic abnormalities between hospitalized Coronavirus disease 2019 (COVID-19) positive and negative patients with correlation to disease severity and outcome.
    J Med Virol. 2022 Apr 25. doi: 10.1002/jmv.27793.
    >> Share

  737. COLSON P, Fournier PE, Delerce J, Million M, et al
    Culture and identification of a "Deltamicron" SARS-CoV-2 in a three cases cluster in southern France.
    J Med Virol. 2022 Apr 25. doi: 10.1002/jmv.27789.
    >> Share

  738. LANZAFAME M, Gibbin E, Lattuada E, Vento S, et al
    Is monoclonal antibody administration necessary in all vaccinated patients with breakthrough COVID-19 infections?
    J Med Virol. 2022 Apr 22. doi: 10.1002/jmv.27802.
    >> Share

  739. PHAN T, Cravener Z, McCullough M, Mays A, et al
    Clinical evaluation of the Cue's COVID-19 diagnostic test to detect.
    J Med Virol. 2022 Apr 22. doi: 10.1002/jmv.27805.
    >> Share

  740. GUO J, Zhang J, Du P, Lu J, et al
    Generation and Characterization of Humanized Synergistic Neutralizing Antibodies against SARS-CoV-2.
    J Med Virol. 2022 Apr 21. doi: 10.1002/jmv.27801.
    >> Share

  741. WANG C, Yang YN, Xi L, Yang LL, et al
    Dynamics of influenza-like illness under urbanization procedure and COVID-19 pandemic in the sub-center of Beijing during 2013-2021.
    J Med Virol. 2022 Apr 21. doi: 10.1002/jmv.27803.
    >> Share

  742. TORRES I, Bellido-Blasco JB, Gimeno C, Burgos JS, et al
    SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty(R) COVID-19 vaccination.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27799.
    >> Share

  743. YE Q, Shao W, Meng H
    Performance and Application Evaluation of SARS-CoV-2 Antigen Assay.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27798.
    >> Share


  744. Corrigendum.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27776.
    >> Share

  745. SUBRAMONEY K, Mtileni N, Bharuthram A, Davis A, et al
    Identification of SARS-CoV-2 Omicron variant using spike gene target failure and genotyping assays, Gauteng, South Africa, 2021.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27797.
    >> Share

  746. KUMAR N, Misra BR, Reddy MM, Deval H, et al
    COVID-19 transmission among vaccinated laboratory workers during the second wave in eastern Uttar Pradesh, India.
    J Med Virol. 2022 Apr 17. doi: 10.1002/jmv.27788.
    >> Share

  747. YAVUZ E, Gunal O, Basbulut E, Sen A, et al
    SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
    J Med Virol. 2022 Apr 17. doi: 10.1002/jmv.27794.
    >> Share

  748. LIN-WANG HT, Lemes RC, Farias EDS, Bajgelman MC, et al
    Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27782.
    >> Share

  749. STEPANEK L, Janosikova M, Stepanek L, Nakladalova M, et al
    The kinetics and predictors of anti-SARS-CoV-2 antibodies up to eight months after symptomatic COVID-19: a Czech cross-sectional study.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27784.
    >> Share

  750. LUCIJANIC M, Soric E, Lacko MS, Sabljic A, et al
    Gradual increase in RDW is similarly prognostic for in-hospital mortality in both anemic and non-anemic COVID-19 patients.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27785.
    >> Share

  751. LIN YF, Li Y, Duan Q, Lei H, et al
    Vaccination strategy for preventing the spread of SARS-CoV-2 in the limited supply condition: a mathematical modelling study.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27783.
    >> Share

  752. OZUDOGRU O, Acer O, Genc Bahce Y
    Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS COV-2 Delta variant dominant period and their clinical characteristics.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27778.
    >> Share

  753. IN E, Altintop Geckil A, Kavuran G, Sahin M, et al
    Using Artificial Intelligence to Improve the Diagnostic Efficiency of Pulmonologists in Differentiating COVID-19 Pneumonia from Community-Acquired Pneumonia.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27777.
    >> Share

  754. MOHAPATRA RK, Kandi V, Tuli HS, Chakraborty C, et al
    The recombinant variants of SARS-CoV-2: concerns continues amid COVID-19 pandemic.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27780.
    >> Share

  755. ALLEN RA, Williams CL, Penrod Y, McCloskey C, et al
    A pyrosequencing protocol for rapid identification of SARS-CoV-2 variants.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27770.
    >> Share

  756. AHMED KAHM, Hasabo EA, Haroun MS, Eljack MMF, et al
    Clinical Characteristics, Complications and Predictors of Outcome of Hospitalized Adult Sudanese Patients with COVID-19 and Malaria Co-Infection in Sudan: A Multi-Center Retrospective Cross-sectional Study.
    J Med Virol. 2022 Apr 12. doi: 10.1002/jmv.27771.
    >> Share

  757. ZHAI SL, Li CL, Sun MF, Zhang JF, et al
    Natural infections of SARS-CoV-2 increased in animals: How should humans get along with animals?
    J Med Virol. 2022 Apr 12. doi: 10.1002/jmv.27772.
    >> Share

  758. LAPIC I, Antolic MR, Horvat I, Premuzic V, et al
    Association of polymorphisms in genes encoding prothrombotic and cardiovascular risk factors with disease severity in COVID-19 patients: a pilot study.
    J Med Virol. 2022 Apr 12. doi: 10.1002/jmv.27774.
    >> Share

  759. BOGLIONE L, Dodaro V, Meli G, Rostagno R, et al
    Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: a case-control study.
    J Med Virol. 2022 Apr 11. doi: 10.1002/jmv.27768.
    >> Share

  760. MEHRAEEN E, SeyedAlinaghi S, Karimi A
    The Post-Omicron Situation: The End of the Pandemic or a Bigger Challenge?
    J Med Virol. 2022 Apr 6. doi: 10.1002/jmv.27765.
    >> Share

  761. GAMA S
    RDW shows prognostic potential in hospitalised patients with COVID-19.
    J Med Virol. 2022 Apr 6. doi: 10.1002/jmv.27764.
    >> Share

  762. AL-BASSAM WW, Al-Karaawi IA, Sharquie IK, Ad'hiah AH, et al
    Evaluation of interleukin-38 levels in serum of patients with coronavirus disease 2019.
    J Med Virol. 2022 Apr 6. doi: 10.1002/jmv.27762.
    >> Share

  763. ABORODE AT, Awuah WA, Mehta A, Abdul-Rahman T, et al
    Concern over Nipah Virus Cases Amidst the COVID-19 Pandemic in India.
    J Med Virol. 2022 Apr 5. doi: 10.1002/jmv.27745.
    >> Share

  764. ELIE B, Roquebert B, Sofonea MT, Trombert-Paolantoni S, et al
    Variant-specific SARS-CoV-2 within-host kinetics.
    J Med Virol. 2022 Apr 4. doi: 10.1002/jmv.27757.
    >> Share


  765. Dominant clade-featured SARS-CoV-2 co-occurring mutations reveal plausible epistasis: An in silico based hypothetical model.
    J Med Virol. 2022 Apr 4. doi: 10.1002/jmv.27733.
    >> Share

  766. YE C, Lv Y, Kuang W, Yang L, et al
    Inactivated vaccines prevent severe COVID-19 in patients infected with the Delta variant: a comparative study of the Delta and Alpha variants from China.
    J Med Virol. 2022 Apr 2. doi: 10.1002/jmv.27759.
    >> Share

  767. BHATNAGAR S, Jones K, Montoya A
    COVID-19 Vaccine Side Effects among Nursing Home Residents and Staff.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27756.
    >> Share

  768. KWOK CS, Muntean EA, Mallen CD
    The impact of COVID-19 on the patient, clinician, healthcare services and society: A patient pathway review.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27758.
    >> Share

  769. KAYGUSUZ S, Korukluoglu G, Cosgun Y, Sahin O, et al
    INVESTIGATION AND LONG-TERM MONITORING OF THE PRESENCE OF NEUTRALIZING ANTIBODY IN PATIENTS WITH COVID-19 DISEASE OF DIFFERENT CLINICAL SEVERITY.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27751.
    >> Share

  770. GAUTRET P, Hoang VT, Jimeno MT, Lagier JC, et al
    Severity of the first 207 infections with the SARS-CoV-2 Omicron BA.2 variant, in Marseille, France, December, 2021-February, 2022.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27760.
    >> Share

  771. CHIRUMBOLO S
    Antioxidants associated with NSAIDs might even exacerbate the progress of SARS-CoV2 disease.
    J Med Virol. 2022;94:1264-1266.
    >> Share

    March 2022
  772. CHAI C, Chen K, Li S, Cheng G, et al
    Effect of elevated fasting blood glucose level on the one-year mortality and sequelae in hospitalized COVID-19 patients: a bidirectional cohort study.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27737.
    >> Share

  773. PENNEY J, Jung A, Koethe B, Doron S, et al
    Cycle Threshold Values and SARS-CoV-2: Relationship to Demographic Characteristics and Disease Severity.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27752.
    >> Share

  774. TAMARIZ L, Bast E, Abad M, Klimas N, et al
    Letter to the editor: Post COVID-19 joint pain: Preliminary report of the relationship with antinuclear antibodies and inflammation.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27753.
    >> Share

  775. CHEN C, Feng Y, Chen Z, Xia Y, et al
    SARS-CoV-2 cold-chain transmission: Characteristics, risks and strategies.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27750.
    >> Share

  776. YANG S, Cao L, Xu W, Xu T, et al
    Comparison of model-specific histopathology in mouse models of COVID-19.
    J Med Virol. 2022 Mar 30. doi: 10.1002/jmv.27747.
    >> Share

  777. COTO E, Albaiceta GM, Amado-Rodriguez L, Garcia-Clemente M, et al
    FURIN gene variants (rs6224/rs4702) as potential markers of deat hand cardiovascular traits in severe COVID-19.
    J Med Virol. 2022 Mar 30. doi: 10.1002/jmv.27748.
    >> Share

  778. RAJPAL VR, Sharma S, Kumar A, Chand S, et al
    'Is Omicron mild'? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies.
    J Med Virol. 2022 Mar 30. doi: 10.1002/jmv.27749.
    >> Share

  779. SINGH R, Kaur U, Singh A, Chakrabarti SS, et al
    Refractory hyper-eosinophilia associated with newly diagnosed rheumatoid arthritis following inactivated BBV152 COVID-19 vaccine.
    J Med Virol. 2022 Mar 29. doi: 10.1002/jmv.27742.
    >> Share

  780. REITER RJ, Sharma R, Tan DX, Neel RL, et al
    Melatonin Use for SARS-CoV-2 Infection:Time to Diversify the Treatment Portfolio.
    J Med Virol. 2022 Mar 26. doi: 10.1002/jmv.27740.
    >> Share

  781. WANG W, Peng X, Jin Y, Pan JA, et al
    Reverse genetics systems for SARS-CoV-2.
    J Med Virol. 2022 Mar 24. doi: 10.1002/jmv.27738.
    >> Share

  782. CHEN Q, Huang XY, Liu Y, Sun MX, et al
    Comparative characterization of SARS-CoV-2 variants of concern and mouse-adapted strains in mice.
    J Med Virol. 2022 Mar 23. doi: 10.1002/jmv.27735.
    >> Share

  783. ZHU G, Zhou S, Xu Y, Gao R, et al
    Mendelian randomization study on the causal effects of COVID-19 on childhood intelligence.
    J Med Virol. 2022 Mar 23. doi: 10.1002/jmv.27736.
    >> Share

  784. YANG S, Zhou H, Liu M, Jaijyan D, et al
    SARS-CoV-2, SARS-CoV and MERS-CoV encode circular RNAs of spliceosome-independent origin.
    J Med Virol. 2022 Mar 22. doi: 10.1002/jmv.27734.
    >> Share

  785. OZTAS M, Bektas M, Karacan I, Aliyeva N, et al
    Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27731.
    >> Share

  786. MASYENI S, Iqhrammullah M, Frediansyah A, Nainu F, et al
    Molnupiravir: a lethal mutagenic drug against rapidly mutating SARS-CoV-2 - A narrative review.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27730.
    >> Share

  787. FERNANDEZ-DE-LAS-PENAS C, Martin-Guerrero JD, Navarro-Pardo E, Torres-Macho J, et al
    Exploring the recovery curve for gastrointestinal symptoms from the acute COVID-19 phase to long-term post-COVID: The LONG-COVID-EXP-CM Multicenter Study.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27727.
    >> Share

  788. MAGALIS BR, Mavian C, Tagliamonte M, Rich SN, et al
    Low-frequency variants in mildly symptomatic vaccine breakthrough infections presents a doubled-edged sword.
    J Med Virol. 2022 Mar 20. doi: 10.1002/jmv.27726.
    >> Share

  789. HASSANIAZAD M, Farshidi H, Gharibzadeh A, Bazram A, et al
    Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with covid-19: a randomized clinical trial.
    J Med Virol. 2022 Mar 16. doi: 10.1002/jmv.27724.
    >> Share

  790. TSAGKARIS C, Loudovikou A, Matiashova L, Papadakis M, et al
    Public health concerns over polio in war-torn Ukraine and nearby regions: Four lessons and a warning from the history of epidemics.
    J Med Virol. 2022 Mar 15. doi: 10.1002/jmv.27723.
    >> Share

  791. MISHRA AR, Nayak D, Byrareddy SN
    Are we moving towards ending SARS-CoV-2?
    J Med Virol. 2022 Mar 14. doi: 10.1002/jmv.27722.
    >> Share

  792. YAN Y, Tang YD, Zheng C
    When cyclin-dependent kinases meet viral infections, including SARS-CoV-2.
    J Med Virol. 2022 Mar 14. doi: 10.1002/jmv.27719.
    >> Share

  793. QIN S, Li R, Zheng Z, Zeng X, et al
    Review of selected animal models for respiratory coronavirus infection and its application in drug research.
    J Med Virol. 2022 Mar 13. doi: 10.1002/jmv.27718.
    >> Share

  794. DHEIR H, Tocoglu A, Toptan H, Pinar M, et al
    Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients.
    J Med Virol. 2022 Mar 12. doi: 10.1002/jmv.27714.
    >> Share

  795. SHEN L, Sun M, Song S, Hu Q, et al
    The impact of anti-COVID-19 non-pharmaceutical interventions on hand, foot, and mouth disease-a spatiotemporal perspective in Xi'an, northwestern China.
    J Med Virol. 2022 Mar 11. doi: 10.1002/jmv.27715.
    >> Share

  796. CHAVDA VP, Patel AB, Vaghasiya DD
    SARS-CoV-2 variants and vulnerability at the global level.
    J Med Virol. 2022 Mar 11. doi: 10.1002/jmv.27717.
    >> Share

  797. ARCANI R, Cauchois R, Suchon P, Jean R, et al
    Factors associated with dexamethasone efficacy in COVID-19. A retrospective investigative cohort study.
    J Med Virol. 2022 Mar 11. doi: 10.1002/jmv.27712.
    >> Share

  798. YOSHIOKA N, Deguchi M, Hagiya H, Kagita M, et al
    Comparison of Extraction-based and Elution-based Polymerase Chain Reaction Testing, and Automated and Rapid Antigen Testing for the Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2.
    J Med Virol. 2022 Mar 10. doi: 10.1002/jmv.27709.
    >> Share

  799. GHAFOURI M, Saadati H, Taghavi MR, Azimian A, et al
    Survival of the hospitalized patients with COVID-19 receiving Atorvastatin: a randomized clinical trial.
    J Med Virol. 2022 Mar 10. doi: 10.1002/jmv.27710.
    >> Share

  800. XIAO F, Wan P, Wei Q, Wei G, et al
    Prolonged fecal shedding of SARS-CoV-2 in a young immunocompetent COVID-19 patient: a case report and literature overview.
    J Med Virol. 2022 Mar 10. doi: 10.1002/jmv.27694.
    >> Share

  801. ARORA G, Taneja J, Bhardwaj P, Goyal S, et al
    Adverse events and Breakthrough infections associated with COVID-19 vaccination in the Indian population.
    J Med Virol. 2022 Mar 8. doi: 10.1002/jmv.27708.
    >> Share

  802. DIRICAN E, Savrun ST, Aydin IE, Gulbay G, et al
    ANALYSIS OF MITOCHONDRIAL DNA CYTOCHROME-B (CYB) and ATPase-6 GENE MUTATIONS IN COVID-19 PATIENTS.
    J Med Virol. 2022 Mar 8. doi: 10.1002/jmv.27704.
    >> Share

  803. CAI C, Tang YD, Zheng C
    When RING Finger Family Proteins meet SARS-CoV-2.
    J Med Virol. 2022 Mar 7. doi: 10.1002/jmv.27701.
    >> Share

  804. LIU N, Long H, Sun J, Li H, et al
    New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression.
    J Med Virol. 2022 Mar 5. doi: 10.1002/jmv.27693.
    >> Share

  805. CHENCHULA S, Karunakaran P
    Current Evidence on Efficacy of COVID-19 Booster Dose Vaccination Against the Omicron Variant. A Systematic Review.
    J Med Virol. 2022 Mar 4. doi: 10.1002/jmv.27697.
    >> Share

  806. RAMIREZ JD, Castaneda S, Ballesteros N, Munoz M, et al
    Hotspots for SARS-CoV-2 Omicron Variant Spread: Lessons from New York City.
    J Med Virol. 2022 Mar 3. doi: 10.1002/jmv.27691.
    >> Share

  807. COLSON P, Delerce J, Beye M, Levasseur A, et al
    First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France.
    J Med Virol. 2022 Mar 3. doi: 10.1002/jmv.27695.
    >> Share

  808. TSUCHIDA T, Hirose M, Inoue Y, Kunishima H, et al
    Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID.
    J Med Virol. 2022 Mar 2. doi: 10.1002/jmv.27689.
    >> Share

  809. MARGIOTTI K, Fabiani M, Mesoraca A, Giorlandino C, et al
    Survey of fully vaccinated anti-COVID 19 people from June to November 2021: Single Italian centre study.
    J Med Virol. 2022 Mar 2. doi: 10.1002/jmv.27690.
    >> Share

  810. OLIVEIRA GS, Silva-Flannery L, da Silva JF, Siza C, et al
    Active surveillance and early detection of community transmission of SARS-CoV-2 Mu variant (B.1.621) in the Brazilian Amazon.
    J Med Virol. 2022 Mar 2. doi: 10.1002/jmv.27686.
    >> Share

  811. CICCARESE G, Drago F, Marinaro E, Parodi A, et al
    PITYRIASIS ROSEA DURING COVID-19: PATHOGENESIS, DIAGNOSIS AND TREATMENT.
    J Med Virol. 2022 Mar 1. doi: 10.1002/jmv.27672.
    >> Share

  812. LIMA ARJ, Ribeiro G, Viala VL, Lima LPO, et al
    SARS-COV-2 GENOMIC MONITORING IN THE STATE OF SAO PAULO UNVEILS TWO EMERGING AY.43 SUBLINEAGES.
    J Med Virol. 2022 Mar 1. doi: 10.1002/jmv.27674.
    >> Share

    February 2022
  813. GIANNOS P, Prokopidis K
    Gut Dysbiosis and Long COVID-19: Feeling Gutted.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27684.
    >> Share

  814. NOTARTE KI, Guerrero-Arguero I, Velasco JV, Ver AT, et al
    Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27688.
    >> Share

  815. LETAFATI A, Aghamirmohammadali FS, Rahimi-Foroushani A, Hasani SA, et al
    No Human Respiratory Syncytial Virus but SARS-CoV-2 in children under 5 years old referred to Children Medical Center in 2021, Tehran, Iran.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27685.
    >> Share

  816. CHIU W, Verschueren L, Eynde CVD, Buyck C, et al
    Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27683.
    >> Share

  817. HAUSLER M, Kleines M
    The SARS-CoV-2 pandemic in Germany may represent the sum of a large number of local but independent epidemics each initiated by individuals aged 10 - 19 years, middle aged males, or elderly individuals.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27682.
    >> Share

  818. ZENG L, Zang F, Song N, Li Z, et al
    Analysis of influenza trend and impact of COVID-19 in Kezhou, Xinjiang for 8 consecutive years.
    J Med Virol. 2022 Feb 25. doi: 10.1002/jmv.27678.
    >> Share

  819. LINSSEN J, Schapendonk C, Munster M, Daemen P, et al
    A method comparison study of the high throughput automated HISCL((R)) SARS-CoV-2 antigen assay using nasopharyngeal swab samples from symptomatic and asymptomatic subjects against conventional RT-PCR.
    J Med Virol. 2022 Feb 25. doi: 10.1002/jmv.27679.
    >> Share

  820. BORDINO V, Marengo N, Garlasco J, Cornio AR, et al
    Cross-sectional study of SARS-CoV-2 seropositivity among health-care workers and residents of long-term facilities in Italy, January 2021.
    J Med Virol. 2022 Feb 24. doi: 10.1002/jmv.27670.
    >> Share

  821. ACER O, Bahce YG, Ozudogru O
    Association of viral load with age, gender, disease severity and death in SARS-CoV-2 variants.
    J Med Virol. 2022 Feb 24. doi: 10.1002/jmv.27677.
    >> Share

  822. LEFEUVRE C, Pivert A, Przyrowski E, Bouthry E, et al
    Comparison of performance between three SARS-CoV-2 molecular assays (Aptima, Laboratory developed test-Fusion and R-GENE(R)) with a special attention on turn-around time, key point in the laboratory management.
    J Med Virol. 2022 Feb 24. doi: 10.1002/jmv.27675.
    >> Share

  823. DUAN Y, Yuan C, Suo X, Cao L, et al
    TET2 is Required for Type I IFN-mediated Inhibition of Bat-Origin Swine Acute Diarrhea Syndrome Coronavirus.
    J Med Virol. 2022 Feb 24. doi: 10.1002/jmv.27673.
    >> Share

  824. YADAV PD, Nyayanit DA, Gupta N, Shastri J, et al
    Detection and isolation of SARS-CoV-2 Eta variant from the international travelers and local residents of India.
    J Med Virol. 2022 Feb 24. doi: 10.1002/jmv.27676.
    >> Share

  825. SOBOLEWSKI KA, Smoke SM, Brophy A, Vassallo AV, et al
    Real world evaluation of the impact of two Anti-SARS-CoV-2 monoclonal antibody regimens on COVID-19 hospitalizations in older adults.
    J Med Virol. 2022 Feb 23. doi: 10.1002/jmv.27668.
    >> Share

  826. PAPPA S, Haidopoulou K, Zarras C, Theodorakou E, et al
    Early initiation of the respiratory syncytial virus season in 2021-2022, Greece.
    J Med Virol. 2022 Feb 23. doi: 10.1002/jmv.27671.
    >> Share

  827. BUSIC N, Lucijanic T, Barsic B, Luksic I, et al
    Vaccination provides protection from respiratory deterioration and death among hospitalized COVID-19 patients: differences between vector and mRNA vaccines.
    J Med Virol. 2022 Feb 20. doi: 10.1002/jmv.27666.
    >> Share

  828. ATA S, Cil T, Duman BB, Unal N, et al
    EVALUATION OF ANTIBODY RESPONSE AFTER TWO DOSES OF THE SINOVAC VACCINE AND THE POTENTIAL NEED FOR BOOSTER DOSES IN CANCER PATIENTS.
    J Med Virol. 2022 Feb 18. doi: 10.1002/jmv.27665.
    >> Share

  829. DESINGU PA, Nagarajan K
    Omicron variant losing its critical mutations in the receptor-binding domain.
    J Med Virol. 2022 Feb 18. doi: 10.1002/jmv.27667.
    >> Share

  830. PASCARELLA S, Bianchi M, Giovanetti M, Narzi D, et al
    The SARS-CoV-2 mu variant shouldn't be left aside: it warrants attention for its immuo-escaping ability.
    J Med Virol. 2022 Feb 16. doi: 10.1002/jmv.27663.
    >> Share

  831. ZHOU JQ, Liu GX, Huang XL, Gan HT, et al
    The importance of fecal nucleic acid detection in patients with coronavirus disease(COVID-19):a systematic review and meta-analysis.
    J Med Virol. 2022 Feb 16. doi: 10.1002/jmv.27652.
    >> Share

  832. HERNANDEZ MM, Riollano-Cruz M, Boyle MC, Banu R, et al
    Food for thought: Eating before saliva collection and interference with SARS-CoV-2 detection.
    J Med Virol. 2022 Feb 16. doi: 10.1002/jmv.27660.
    >> Share

  833. CROSS GB, Naftalin CM, Ngiam JN, Bagdasarian N, et al
    Discrepant serological findings in SARS-CoV-2 PCR negative, hospitalised patients with fever and acute respiratory symptoms during the pandemic.
    J Med Virol. 2022 Feb 16. doi: 10.1002/jmv.27656.
    >> Share

  834. CHEN JM
    Novel statistics predict the COVID-19 pandemic could terminate in 2022.
    J Med Virol. 2022 Feb 11. doi: 10.1002/jmv.27661.
    >> Share

  835. DESINGU PA, Nagarajan K
    Omicron BA.2 lineage spreads in clusters and is concentrated in Denmark.
    J Med Virol. 2022 Feb 11. doi: 10.1002/jmv.27659.
    >> Share

  836. PARIDA SP, Sahu DP, Singh AK, Alekhya G, et al
    Adverse Events Following Immunization of COVID-19 (Covaxin) vaccine at a Tertiary Care Center of India.
    J Med Virol. 2022 Feb 11. doi: 10.1002/jmv.27655.
    >> Share

  837. LAMPEJO DT
    The impact of the COVID-19 pandemic on the global burden of influenza.
    J Med Virol. 2022 Feb 10. doi: 10.1002/jmv.27653.
    >> Share

  838. ZHANG H, Fischer DK, Shuda M, Moore PS, et al
    Construction and characterization of two SARS-CoV-2 minigenome replicon systems.
    J Med Virol. 2022 Feb 9. doi: 10.1002/jmv.27650.
    >> Share

  839. PARK J, Il Shin J, Kim DH, Park J, et al
    Association of atrial fibrillation with infectivity and severe complications of COVID-19: A nationwide cohort study.
    J Med Virol. 2022 Feb 7. doi: 10.1002/jmv.27647.
    >> Share